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ABSTRACT
Isothiocyanates (ITCs) are natural phytochemicals produced by cruciferous vegetables.
Recent evidence supports that, in addition to cancer prevention, ITCs can use various
mechanisms to target malignant cells. Current therapies for cancer often provoke detrimental
side effects, however clinical evidence supports that ITCs have little to no side effects in
patients. Consequently, ITCs may be a promising treatment option for cancer patients, especially
patients suffering from head and neck squamous cell carcinoma (HNSCC).
Despite recent improvements in cancer treatment, overall survival of advanced HNSCC
has not improved in the past three decades. Metastasis and chemoresistance represent two
detrimental events that greatly hinder the outcome for those suffering with HNSCC. Thus, new
therapeutic options to enhance survival of patients with advanced HNSCC are needed. Several
types of ITCs can be used to target HNSCC, however our studies indicated that benzyl
isothiocyanate (BITC) elicits the strongest anti-tumor response when targeting chemoresistant
and metastatic HNSCC cell lines.
In our in vitro studies, we evaluated the use of BITC as a treatment for HNSCC. Our
study had three objectives; the first being to investigate if this compound can prevent HNSCC
cell migration and invasion, the second was to study if BITC could enhance the effects of
chemotherapy, and the third was to identify a mechanism through which BITC was eliciting its
anti-tumor response.
Our in vitro data suggests that treatment with BITC significantly reduced the viability of
multiple HNSCC cell lines tested (HN12, HN8, and HN30), but not a normal keratinocyte cell
line (HAK). BITC treatments also decreased the migration and invasion of the HN12 cell line, in
a dose dependent manner, at concentrations that did not affect cell viability. Additionally, when
xiii

compared to either BITC or cisplatin treatment alone, the reduction in HNSCC cell viability was
greater if a pretreatment of BITC was followed by a treatment of cisplatin.
Furthermore, the expression of the epithelial-mesenchymal transition (EMT) marker,
vimentin, was significantly reduced after a BITC treatment in the HN12 cell line. We also
observed that BITC treatments significantly increased the amount of reactive oxygen species
(ROS) in HNSCC cells. Blocking BITC induced ROS with co-administration of catalase or Nacetyl-L-cysteine (NAC) significantly inhibited BITC’s ability to prevent cellular migration. Coadministration of NAC with BITC prior to cisplatin treatment reduced cytotoxicity as compared
to BITC pre-treatment followed by cisplatin. Therefore, indicating that co-administration of
anti-oxidants with BITC could alter the clinical efficacy BITC.
Taken together these data suggest that BITC has the capacity to inhibit processes
involved in HNSCC cell migration and invasion, as well as add to the effectiveness of
chemotherapy, and both of these events are regulated by BITC induced ROS.
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ABSTRACT
Isothiocyanates (ITCs) are phytochemicals produced from the hydrolysis of
glucosinolates, which are found at high concentrations in cruciferous vegetables. Vegetables of
the Cruciferae family include broccoli, cauliflower, gardencress, watercress, and cabbage. A
number of studies have suggested that the ITCs, sulforaphane (SFN), benzyl isothiocyanate
(BITC), and phenethyl isothiocyanate (PEITC) are capable of preventing breast, lung, and
prostate carcinogenesis. In addition to chemoprevention, SFN, PEITC, and BITC have also been
investigated for their chemotherapeutic potential in numerous cancers. The anti-cancer effects
of SFN, BITC, and PEITC are associated with several cellular pathways that inhibit growth,
induce apoptosis, and prevent metastasis.
Studies investigating the chemopreventive and chemotherapeutic properties of SFN,
PEITC, and BITC are quickly progressing from bench to beside. This chapter will give a brief
overview of SFN, PEITC, and BITC, focusing mainly on these ITC’s reported ability to
inhibit carcinogenesis in vivo and in vitro during three stages: initiation, promotion, and
progression.
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INTRODUCTION
Isothiocyanates (ITCs) are phytochemicals produced by vegetables in the Cruciferae
family [1-3]. Cruciferous vegetables include broccoli, Indian cress, cabbage, Brussels sprouts,
and watercress [4]. ITCs are generated naturally from the hydrolysis of glucosinolates, which
are a secondary metabolite found in cruciferous vegetables, and contain a β-D-thioglucose
group, a sulfonated oxime moiety, and a variable side chain [4]. A cruciferous vegetable
produces ITCs as a defense mechanism when the plant is damaged or “under attack”. This
family of vegetables spatially separates glucosinolates (cytoplasm) from the defense-related
enzyme myrosinase (external surface of the plant cell wall), and when the plant is damaged or
chewed the enzyme and glucosinolate are brought into contact, and the glucosinolate undergoes a
Lossen rearrangement creating the ITC product [5]. The glucosinolate precursor dictates the
type of ITC produced (Table 1.1). There are currently over a 100 glucosinolates identified, but
not all of the corresponding ITCs appear to have anti-carcinogenic properties [2]. Examination
of the literature suggests that the ITCs most frequently investigated for their anti-cancer
effects are sulforaphane (SFN), benzyl isothiocyanate (BITC), and phenethyl isothiocyanate
(PEITC), and are therefore the main focus of this chapter.

Table 1.1 Isothiocyanates with their corresponding glucosinolate precursor and food source.
Isothiocyanate
Benzyl Isothiocyanate (BITC)
Phenethyl Isothiocyanate (PEITC)
Sulforaphane (SFN)

Glucosinolate
(precursor)
Glucotropaeolin
Gluconasturtiin
Glucoraphanin

Food Sources
Cabbage, garden cress, Indian cress
Watercress
Broccoli, Brussels sprouts, cabbage

All ITCs, including SFN, BITC, and PEITC have the same R-N=C=S structure (Figure
1.1). The reactive group is the sulfur containing N=C=S functional group, which is a strong
3

electrophile and can undergo a nucleophilic attack [6]. The N=C=S group is reported to
selectively bind to thiol-containing cysteines and ε-amino containing lysines forming
thiocarbamates and thioureas, respectively [7].

ITCs are suggested to form thiocarbamates

at a 103 to 104 faster rate than thioureas, but are less stable [6,7]. The ability of ITCs to
target cysteine residues is significant, because cysteine residues are often found in the catalytic
site of enzymes [5]. The binding to cysteine residues is suggested to be one way in which ITCs
can alter signal transduction and redox status [2].

Figure 1.1 Chemical structure of BITC,
PEITC, SFN.

The R group of ITCs varies significantly, and can be either an alkyl or aryl group. For
example, SFN contains an alkyl side chain, whereas PEITC and BITC’s side chain is an aryl group
(Figure 1.1). Proteomics studies have indicated that the R group may play an important role in the
targets of ITCs [7,8]. In A549 cells 14C -SFN was shown to bind to only 16 proteins, whereas 14CPEITC was shown to target more than 30 proteins [7]. Additionally, a difference in the
mechanism of action has been reported when investigating PEITC and SFN’s involvement in cell
cycle and apoptosis [5,6]. Furthermore, PEITC and BITC are reported to inhibit cellular
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proliferation, induce apoptosis, and inhibit cellular migration at significantly lower concentrations
than SFN [3,9-11]. This has also been supported in animal models [2,4,12].
Regardless of the mechanism of action, SFN, BITC, and PEITC have all been shown to
inhibit the growth of many cancerous cell lines, including lung, prostate, and breast [13-17].
However, when considering an effective treatment for any disease one must assess whether or
not the treatment is feasible in humans. Many phytochemicals or polyphenols have indicated
promising results in cell culture, but the serum concentrations needed to observe similar effects
in humans has not been achieved. Studies indicate that the oral bioavailabilities of ITCs are
high; suggesting that they may be a better treatment option than other phytochemicals.
The bioavailability of SFN is reported to be high in animals and humans; however there
is limited data on the oral bioavailability in humans. In male Wistar rats 82% of SFN has been
shown to be bioavailable [4,18]. PEITC is also suggested to have a high oral bioavailability in
both animals and humans [5]. Additionally, the AUC per os (p.o.) and intravenous (i.v.)
administration of PEITC does not appear to differ significantly in mice and rats [5,18].
Bioavailability of BITC has only been reported in animals. More than 98% of [7-14C] BITC was
rapidly absorbed following oral administration to Wistar rats [19].
There are significant differences when comparing the half-life and AUC between the
different ITCs. The half-life and AUC of SFN is lower than that reported of PEITC. In humans,
PEITC has a half-life of 3.7 to 4.9 hours; whereas the half-life of SFN is only reported to be 1.8
hrs and 1-2 hours, respectively [5,19]. The half-life of BITC in rats is 1-2 hours [19] .
Interestingly, increasing the dose of PEITC increases the half-life, and decreases the clearance
[2,4,5]. ITC metabolites are secreted in the urine and the saturation of the enzymes involved in
the metabolism of ITCs may be an explanation for the decreased clearance [4].
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Additionally, the accumulation of all ITCs into cells is suggested to be rapid, and the
intracellular concentration is reported to be several hundred-fold greater than the extracellular
concentration [2]. This observation has been supported in mouse pancreatic endothelial and
fibroblast cells, as well as in human prostate and colon cancer cell lines [2,5]. ITCs are also
reported to reach many tissues because they are coupled to serum albumin and can be
systemically transported throughout the body and released into tissues [5].
When considering the transition from bench to bedside, bioavailability is critical for the
success of ITCs, but methods to determine ITC concentrations in humans are still being fine-tuned.
The problem with many of the original methods used for ITC quantification was that they could
only determine total ITC concentration and not specific ITC conjugates. Also, the method for
determining ITC concentration in the urine vs. the blood may need to be different [2,5]. ITCs are
excreted mainly in the urine; therefore the ITC concentration in the urine is very high. The
concentration in the blood is much lower, and the detection method in the serum needs to be more
sensitive to be able to detect the low levels of ITCs [20]. The test also needs to be specific for a
particular ITC, not just ITCs in general. Cyclocondensation is a sensitive test used to detect ITCs;
however, it can only identify the total ITC concentration [5]. This reaction also cannot distinguish
between ITCs and other thionyl compounds. When using blood samples, the cyclocondensation
reaction is not sensitive enough for ITC quantification. An assay using polyethylene glycol
followed by membrane ultrafiltration to remove proteins before high-performance liquid
chromatography (HPLC) is suggested to be better for ITC identification in blood [5]. Another
method for ITC quantification, which can be used for both urine and plasma, involves an ammonia
derivation of ITC to phenethylthiourea and subsequent liquid chromatography/tandem mass
spectrometry (LC-MS/MS) [5]. The advantage of this method is that it allows specific ITCs to be
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identified. This section highlights that, while research on SFN, PEITC, and BITC has come a long
way, a better understanding of the pharmacokinetics and pharmacodynamics, as well methods of
detection are still needed to advance the clinical aspects of ITC research.
Cancer is a multi-stage process involving initiation, promotion and progression and ITCs
are suggested to target each of these stages. The objective for the remainder of this chapter is to
briefly review the evidence for the benefits SFN, BITC, and PEITC treatment in both preventing
and treating multiple cancer types, as well as a rational mechanism for these effects.

Mechanisms of Action
The mechanism of action involved in the anti-carcinogenic and anti-tumor activity of
ITCs have not been fully elucidated. However, the mechanism involved in ITCs ability to
inhibit carcinogenesis is more fully understood and involves the inhibition of carcinogen
activation. ITCs are known to inhibit the activity of several cytochrome p450s (CYP450),
which are Phase I enzymes involved in normal metabolism, and also in carcinogen activation
[1,6,21]. By inhibiting the activity of CYP450s, ITCs can prevent DNA adduct formation and
the subsequent mutation leading to a transformed cell, thereby preventing carcinogenesis. ITCs
also induce certain Phase II enzymes, like GST, through activation of the Keap-1/Nrf2 pathway
[2,6]. The induction of Phase II enzymes helps dispose of activated carcinogens by transforming
the carcinogen into a water-soluble compound that can be excreted via the urine [6].
Additionally, ITC treatments are suggested to rapidly decrease the concentration of reduced
glutathione (GSH) in cells, which can prevent tumor formation [22]. Hyperplasic cells usually
have mutations that lead to an increase of reactive oxygen species (ROS) and are sensitive to
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GSH depletion [23]. A depletion of GSH can induce apoptosis, thereby preventing the
progression of a pre-neoplastic lesion to a malignant tumor.

Figure 1.2 Molecular pathways targeted by SFN, BITC, and
PEITC.

The anti-tumor activity of these ITCs affect various
molecular targets that inhibit cell cycle and angiogenesis,
and induce apoptosis.

The mechanisms involved in the anti-tumor activity of ITCs are more complex than the
mechanisms linked to chemoprevention. In cancerous cells, ITCs target several different
molecular pathways linked to apoptosis, cell cycle arrest, and migration [2,4,24,25]. However,
evidence supports that the type of ITC, as well as the concentration, has a significant effect on
the mechanism of action. The protein kinase B (AKT), extracellular signal-regulated kinases
(ERK), and p38 MAP kinase (p38) pathways are frequently discussed in relation to SFN,
PEITC, and BITC treatment [1,2,4]. Alterations in additional pathways are also linked to ITC
therapy, as highlighted in Figure 1.2, and will be discussed more thoroughly in the following
sections [1,2].

8

The mechanism involved in ITC’s ability to trigger apoptosis is complex and therefore
deserves some discussion. SFN, PEITC, and BITC induce apoptosis in numerous cancer cell
lines; however, induction of apoptosis is different between the treatments [4]. PEITC and BITC
can initiate apoptosis by binding to tubulin [4,7]. Dysfunction of tubulin increases the cleavage
of caspase-8 and-9. SFN does not have a strong affinity for tubulin, but does induce ROS more
potently that PEITC. SFN, PEITC, and BITC are all shown to decrease the anti-apoptotic
proteins Bcl-2 and Bcl-xL [4,26]. Additionally, these ITCs induce caspase-3 activity and PARP
cleavage [1,27,28]. Studies on PEITC suggest that this ITC has the ability to stimulate
caspase-3, -8, and-9 [2]. However, in leukemia cells, it has been shown that caspase-8 is
critical and caspase-3 only provides a supporting role [29]. Therefore, studies support that
treatment with ITCs initiate apoptosis through both extrinsic and intrinsic mechanisms. The proapoptotic protein BID also appears to be cleaved in response to ITC treatment indicating that the
c-Jun terminal kinase (JNK) pathway is a target of ITCs [4,30]. SFN, BITC, and PEITC, have
all been shown to target the JNK pathway in various cancer cells. Interestingly, in OVAR-3
cells, PEITC suppressed the activation of Akt and ERK1/2, but activated the p38 and JNK1/2
pathway.
Treatments with SFN, PEITC, or BITC induce cell cycle arrest, but literature varies on
the type of cell cycle arrest initiated by each ITC. SFN and BITC are both reported to induce
G2/M arrest, while PEITC is reported to induce G0/G1 arrest [25,27,31]. However, these studies
were done on different cancer cell lines with different concentrations that could account for the
different results. In all reported cases, cell cycle arrest after ITC treatment is associated with an
increase in cyclin-dependent kinase inhibitor 1 (p21/WAF1) and checkpoint kinase 2 (chk2)
[25,27,31,32]. SFN, PEITC and BITC are also all reported to down-regulate expression of
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cdc25c, cyclin D1, and cyclin B1 [25,27,31,32]. Additionally, PEITC is reported to downregulate cyclin A, and SFN and PEITC are both reported to inhibit cyclin E [3,27,31,32].
The mechanisms involved in the inhibition of angiogenesis after ITC treatment are
associated with some of the same pathways linked to apoptosis induction. ITCs are known to
inhibit the Akt pathway, and this pathway activates mTOR, which consequently activates the 4EBinding protein (4E-BP). The 4E-BP regulates expression of HIF-1α. SFN, PEITC, and BITC
inhibit HIF-1α expression and subsequently the factors regulated by HIF-1α, which are involved
in angiogenesis and epithelial-mesenchymal transition (EMT) [17,33,34]. Treatment of prostate
cancer PC-3 cells with PEITC also decreased expression of the angiogenic factors, epidermal
growth factor and colony-stimulating factor [24]. PEITC and BITC treatment both cause a
decrease in the expression of vascular endothelial growth factor (VEGF) [35].
SFN, PEITC, and BITC have all been shown to inhibit migration and invasion of cancer
cells in vitro [13,33,34,36,37]. SFN, PEITC, and BITC have also been shown to suppress the
metastatic potential of breast and NSCLC cells in vivo [38-42]. Suppression of metastasis is
suggested to occur through modulation of metastasis-related gene expression and inhibition of
the Akt/ NF-κB pathway. All three ITCs have been demonstrated to inhibit NF-κB activity in a
dose dependent manner. The inhibition of NF-κB activity appears to be a critical target of ITCs,
in some cancer cell lines. Inhibition of NF-κB can lead to the inhibition of cell growth, induce
apoptosis, and inhibit migration. However, our results suggest that BITC treatment increases
NF-κBp50 activity in HNSCC cell lines, indicating that the link between NF-κB activity and ITC
treatment is not clear cut.
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Uses in Cancer Therapy
Traditional anti-cancer treatments are associated with debilitating side effects. Using
ITCs as a chemotherapy or adjuvant therapy is a novel way to target cancer without the
associated side effects linked to most cancer treatment. ITC treatments alone are reported to
inhibit cell growth, induce apoptosis, and decrease metastasis in vivo and in vitro [2]. As an
adjuvant therapy ITCs sensitize cancer cells to chemo and radiation therapy [28,29,43-47]. ITCs
also target cancer stem cell (CSC) populations, which are the major cause for cancer recurrence
and drug resistance [2,43,48]. According to the ‘‘cancer stem cell” theory, tumors are not to be
viewed as simple monoclonal expansions of transformed cells, but rather as complex tissues
where abnormal growth originates from a pathological minority of cancer stem cells [48]. These
cells have maintained stem-like characteristics in that they proliferate very slowly and have an
inherent capacity to self-renew and differentiate into phenotypically heterogeneous, aberrant
progeny. The following sections give a limited overview of studies that have reported the anticancer effects of ITCs in both in vivo and in vitro model systems.

Lung Cancer
The nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is found in
cigarettes and is a major pro-carcinogen linked to lung cancer formation [2]. The results of
several studies have indicated certain ITCs can inhibit the formation of NNK induced lung
cancer. These studies have led to a Phase II clinical trial (NCT00691132), to determine the
effects of PEITC in participants who smoke only deuterated NNK cigarettes. The endpoint this
study is to determine if PEITC consumption affects the urinary levels of NNK biomarkers in
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current smokers. This research group will also determine if there are changes in cell
proliferation or apoptotic bodies in lung biopsies taken after ingesting PEITC or placebo [10].
In animal models, SFN and PEITC have both shown to inhibit lung tumor formation and
progression. SFN and PEITC both induced apoptosis in lung tissue of A/J mice in which
cigarette carcinogens had induced a lung adenoma [2,10]. SFN and PEITC also inhibited the
progression of adenomas to adenocarcinomas in the lung, implying that these treatments are
useful in lung cancer chemoprevention [2,10]. In cell culture experiments, using various nonsmall-cell lung carcinoma (NSCLC) cell lines SFN, BITC, and PEITC have all been shown to
inhibit cellular proliferation at low concentrations [28,35,49]. Additionally, both SFN and
PEITC induced apoptosis in A549 lung cells after treatment with 20μM and 40μM of each ITC
for 24 hours [49]. In several studies PEITC was shown to be a stronger inducer of apoptosis than
SFN [2].
PEITC and BITC were reported to reduce migration and invasion of the highly metastatic
NSCLC cell line, L9981 [35]. This study also demonstrated that BITC and PEITC inhibited
phosphorylation of AKT, while also inhibiting activity of NF-κB and reducing metastasis related
gene expression [35]. Additionally, Di Pasqua et al. (2010) showed that pretreatment with 10
μM of BITC or PEITC sensitized NCI-H596 NSCLC cells to cisplatin [28].

Breast Cancer
ITC consumption has been linked with a reduction in the risk of breast cancer for some
time, and has recently been investigated as a breast cancer treatment option [17,21,40].
Currently, there are three clinical trials recruiting breast cancer patients, all of which are in Phase
II. Two studies are to determin if the consumption of broccoli sprout extract (SFN) can alter
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proliferation of breast tissue (NCT00982319 and NCT00843167). The study being completed by
the Shannon lab in Oregon (NCT00843167) is focusing on histone deacetylase (HDAC) activity
and apoptosis in women diagnosed with breast cancer, ductal carcinoma in situ and/or atypical
hyperplasia. Additionally, a clinical trial being sponsored by the Sidney Kimmel Comprehensive
Cancer Center (NCT00894712) is assessing the protective effects of topical SFN administration
on radiation-induced dermatitis in women undergoing external-beam radiation therapy for breast
cancer.
Several animal feeding studies have indicated that ITC treatment can inhibit breast cancer
carcinogenesis. Recently it was published that BITC consumption could inhibit mammary
carcinogenesis in MMTV-neu mice [34]. The results of this study suggested that a diet
supplemented with 3mmol BITC/kg of chow could significantly decrease the number of Ki-67
positive cells and increase the number of apoptotic bodies in mammary tumors [40].
SFN, BITC, and PEITC are reported to inhibit cell growth and induce apoptosis in breast
cancer cell lines, such as the MCF-7 cell line [11,49]. Additionally, BITC was reported to inhibit
epithelial-mesenchymal transition (EMT) in the MDA-MB-231 human breast cancer cell line.
This was also supported in xenografted human breast cancer cells [39]. Moreover, BITC was
shown to inhibit hypoxia inducible factor (HIF1-α) expression and activity in MCF-7 cells by
targeting the 4E binding protein 1 (4E-BP1) [15,17].
Studies that target cancer stem cells are currently of great interest, and SFN was found to
decrease the cancer stem cell marker, aldehyde dehydrogenase-1 (ALDH-1), in MCF-7 and
SUM159 human breast cancer cell lines [50]. Additionally, daily injections of SFN (50 mg/kg)
for 2 weeks reduced the number of ALDH-1 positive cells by 50% in non-obese/severe
combined immunodeficient mice with SUM159 xenograft tumors [36]. Treatment with SFN
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also decreased the number of primary mammospheres, which are known to have cancer stem-like
cell properties, by 8- to 125-fold in these two cell lines (MCF-7 and SUM159) [50].

Prostate Cancer
Epidemiological evidence is mixed when investigating the relationship between
cruciferous vegetable consumption and prostate cancer. In eight case-control studies published
since 1990, the results of four studies showed a significantly lower incidence of prostate cancer
in men who consumed large amounts of cruciferous vegetable [1,16,21]. The other four studies
indicated that there was no significant difference. Limiting the analysis to men who are positive
for prostate specific antigen (PSA) appears to decrease some bias and show a stronger link
between ITC consumption and the reduction of prostate cancer [16].
A current clinical trial (NCT01265953) is attempting to identify mechanisms by which
SFN capsules can alter gene expression via epigenetic modifications in patients at risk for
prostate cancer development. The investigators are particularly interested in studying SFN’s
effects on HDAC and DNA methylation in biopsies from men at risk for prostate cancer. ITCs
are also reported to target prostate tumors, and there is a Phase II clinical trial (NCT01228084)
which is recruiting patients with recurrent prostate cancer. This trial will determine if treatment
with SFN can decrease PSA levels within 20 weeks of the SFN treatment.
In addition to the clinical trials, the goals of many in vivo and in vitro studies were to
investigate ITC’s ability to inhibit and target prostate cancer [1,14,24,30]. Xiao et al. (2010)
recently published that PEITC can sensitize PC-3 and DU145 cells to docetaxel [51]. In the
same study, intraperitoneally injected PEITC in combination with docetaxel was shown to upregulate pro-apoptotic proteins (Bax and Bak) greater than either PEITC or docetaxel treatment
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alone in PC-3 xenografts in male athymic mice [51]. Additionally, treatment with PEITC and
docetaxel combined inhibited average tumor volume significantly more than either treatment
alone. One mechanism proposed by which ITCs can exhibit antitumor effects on prostate cancer
cells is via the JAK/STAT3/IL6 pathway [14,30,35,52]. The results of two independent studies
have suggested that both SFN and PEITC can inhibit STAT3 activation and IL-6 production
[15,32]. Inhibition of STAT3 activation is proposed to be one way in which ITCs produce proapoptotic effects [14]. Additionally, BITC treatments were found to inhibit cellular growth and
induce G2/M cell cycle arrest in DU145 cells [30]. Treatment with BITC also stimulated
apoptosis in DU145 cells through the release of apoptosis-inducing factor (AIF) and
endonuclease G (endoG) from the mitochondria, and promoted caspase-3 activation [53].

Pancreatic Cancer
Currently, there are no clinical trials investigating the effects of ITCs on the prevention or
treatment of pancreatic cancer. However, several animal models have suggested that BITC,
PEITC, and SFN can inhibit pancreatic tumor formation. For example, in an animal model using
Syrian Hamsters, PEITC was shown to inhibit the formation of N-nitrobis (2-oxypropyl) amine
(BOP)-induced pancreatic tumors [54]. In cell culture, BITC and PEITC are reported to inhibit
NF-kB activity, STAT3 activation, and induce reactive oxygen species [25,55,56]. Additionally,
SFN alone or in combination with tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) significantly reduced the growth of pancreatic tumors that are rich in tumor initiating
cells, or cancer stem cells, while not causing cytotoxic or adverse effects in normal pancreatic
cancer cells [57]. Rausch et al. (2010) also suggested that SFN in combination with sorafenib
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has a synergistic effect in targeting pancreatic cancer stem cells, by decreasing clonogenicity,
spheroid formation, and ALDH1 activity [43].

Hematological Cancer
Literature indicates that PEITC has been of significant interest in treating various
hematological cancers, such as Acute Myeloid Leukemia (AML) and multiple myeloma [2]. A
Phase I clinical trial (NCT00968461) was scheduled to begin in January of 2012 by the MD
Anderson Cancer Center. The objective of the study is to identify the highest tolerable dose
of orally administered PEITC that can be given to patients who have lymphoproliferative
disorders and have previously been treated with the drug fludarabine.
An in vitro study of great clinical interest demonstrated that primary Chronic
Lymphocytic Leukemia (CLL) cells, both resistant and responsive to fludarabine, were highly
sensitive to PEITC with an IC50 of 5.4 and 5.1 μmol/L, respectively [29]. However, normal
lymphocytes did not show sensitivity to PEITC until 27 μmol/L [29]. In other cell culture
experiments, PEITC treatments inhibit cellular growth and induce apoptosis in the U937, Jurkat,
and HL-60 human leukemia cell lines [58].
SFN and PEITC treatments inhibited proliferation of primary human acute myeloid
leukemia (AML) cells in vivo and in vitro [58,59]. In AML cell lines, both SFN and PEITC
induced cleavage of PARP and caspases-3 and-9 in a concentration dependent manner [3,60].
PEITC treatments also inhibited NF-κB, activated the JNK pathway, and inhibited the AKT
pathway in the U937 human leukemia cell line, indicating a mechanism through which PEITC
can induce apoptosis [58].
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Head and Neck Cancer
Studies investigating the effects of ITCs on Head and Neck Cancer are limited. A few
epidemiologic and basic research studies have suggested that a diet rich in cruciferous vegetables
may reduce the risk of developing primary head and neck tumors [61]. As with NSCLC,
smoking is the biggest risk factor for head and neck squamous cell carcinoma (HNSCC) [62].
Numerous reports using either animal models and human subjects suggest that ITCs can reduce
the activity of carcinogens found in cigarettes, such as NNK [54]. All the in vivo studies to date
have looked at inhibition of lung carcinogenesis in response to cigarette carcinogens. Future
studies need to investigate if ITCs can reduce the incidence of NNK induced HNSCC
carcinogenesis in animal models.
However, as with the other cancers, BITC, PEITC and SFN inhibited proliferation of
HNSCC cell lines in vitro [2,44,61]. BITC also induced caspase-3 and PARP cleavage in the
UM-22B and 1483 HNSCC cell lines in a time dependent manner [63]. In addition, BITC
induced rapid activation of p38 MAPK, as well as activation of p44/MAPK in these same cell
lines [61,63]. Another HNSCC study showed that a combination of SFN and radiation might
produce a synergistic effect in decreasing proliferation in four HNSCC cell lines [45]. This
study also indicated that a combination of SFN and chemotherapy increased apoptosis of
HNSCC cell lines greater than treatment with either SFN or radiation alone. Data generated in
our laboratory also suggested that BITC pretreatment sensitizes the highly resistant HN12, HN30
and HN8 HNSCC cell lines to cisplatin [44]. Additionally, we observed that BITC appears to
inhibit migration of the HN12 HNSCC cell line in a dose dependent manner (Figure 1.3).
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Figure 1.3 BITC and PEITC treatments inhibit wound healing in the HN12 cell line.
(A) Inverted light microscope images of HN12 cells 24 hours after cells were treated with
BITC (2.5-5µM) for 1-hour. (B) Inverted light microscope images of HN12 cells 24 hours
after cells were treated with PEITC (2.5-5µM) for 1-hour. Dashed lines represent scratch
size before treatment. Magnification 100X.
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Conclusions
This chapter highlights the chemopreventive and chemotherapeutic potential of SFN,
PEITC, and BITC. We discussed in vitro and in vivo data indicating that SFN, PEITC, and BITC
treatments inhibit cellular proliferation, induce apoptosis, prevent metastasis, and inhibit
angiogenesis of various cancers. We also provided evidence that ITCs can chemosensitize cancer
cells. Interestingly, evidence also supports the notion that ITCs target cancer stem cells in
breast, prostate, and pancreatic cancer. Furthermore, results from ITC clinical trials, while
limited, suggest that the administration of SFN, BITC, or PEITC are safe treatment options and
clinically relevant concentrations can be achieved.
The goal of this thesis is to further expand the knowledge of ITCs as a cancer treatment
option. This chapter briefly highlighted the use of ITCs in HNSCC, and in following chapters
we will present further results of studies to determine if BITC is a possible therapy option for
HNSCC. Prior to presenting our findings on BITC treatment in HNSCC we will discuss why the
need for new and alternative therapies for HNSCC is so important.
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Chapter 2 : Head and Neck Squamous Cell Carcinoma
Epidemiology and Characterization
In the United States, head and neck cancer accounts for 3% of all malignancies and there
are approximately 55,000 new cases each year and 12,000 related deaths [64]. Worldwide, head
and neck cancer represents the sixth most common form of cancer, with over half a million new
cases identified each year [65]. Two-thirds of head and neck cancer cases occur in industrialized
nations and a predominant amount of patients are males in their 6th and 7th decade of life [66].
Head and neck cancer encompasses every type of tissue in the head and neck region,
including the oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx [66]. Head and
neck squamous cell carcinoma (HNSCC) is the most prevalent form of head and neck cancer,
and accounts for over 90% of all head and neck cancer cases [66]. HNSCC often develops from
easily treatable dysplastic lesions; however most cases are not identified at this stage. More than
60% of HNSCC cases have with loco-regional (stage III) or distant metastasis (stage IV) at the
time of diagnosis [67]. The five-year survival rate for localized HNSCC (stage I) and locally
advanced with minimal lymph node involvement (stage II) is 80-90% [67]. However, the fiveyear survival rate is 20-50% for stage III and 10-30% for Stage IV [67].
A large portion of HNSCC cases are identified at stage III and IV, and not earlier stages
due to the nature of the symptoms correlated with this type of cancer. The symptoms of HNSCC
are often non-specific and can be attributed to other health conditions. For example, sore throat,
nasal congestion, and hoarseness are common HNSCC symptoms and are often mistaken as the
common cold, delaying proper diagnosis.
Major risk factors for developing HNSCC are tobacco use, alcohol consumption, and
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infection with certain types of human papillomavirus (HPV) [66,68,69]. Additional risk factors
include UV radiation, exposure to certain environmental toxins, and additional strains of viruses
outside of the HPV spectrum, such as Epstein-Barr virus [66]. Certain risk factors are localized
to specific regions. For example, in India there are a large number of people who use betel quids
containing the aracea nut and this accounts for 50% of male HNSCC cases and 90% of female
HNSCC cases [70]. However, the biggest universal risk factor for developing HNSCC is
combining alcohol consumption with tobacco use, and this combination has been found to have a
synergistic effect in inducing HNSCC [68].
Reports suggest that avoiding exposure to tobacco and alcohol products could reduce
HNSCC by 90% [66]. A decrease in incidence of HNSCC in certain areas of the world is
attributed to programs that educate the general public about the link between smoking, alcohol,
and HNSCC. However, an increase in HPV infections in the Western world is diminishing the
progress of reducing HNSCC [71]. While most cases of HNSCC are caused by tobacco and
alcohol use, HPV-related head and neck cancers are on the rise [71]. HPV associated HNSCC
account for a large portion of oropharynx cancers (cancer in the tonsils or the back of the tongue)
[72]. In fact, it is reported that up to 80% of oropharyngeal cancers in the United States are due
to infection with the HPV virus [71,73].
The identification of HPV as a risk factor for HNSCC is relatively new, and the presence
of the HPV virus significantly alters a patient’s treatment plan [71]. Research indicates that
tumors initiated by HPV respond differently to treatments than tumors initiated by other causes,
mainly because the genetic mutations and cellular pathways manipulated by HPV are different
from the ones affected by other carcinogens [73].
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Classification and Staging
There are eight types of HNSCC identified: conventional, verrucous, basaloid, papillary,
spindle cell (sarcomatoid), acantholytic, adenosquamous, and cuniculatum [74]. Each of these
variants can develop in any of the head and neck regions (oral cavity, nasopharynx, oropharynx,
hypopharynx, and larynx), except for cuniculatum (which is only identified in oral mucosa) [74].
HNSCC can be well-, moderately-, or poorly-differentiated and the histological grades used to
classify HNSCC are found in Table 2.1. Most HNSCC cases are moderately to poorlydifferentiated [74].

Table 2.1 Histological Grade used for HNSCC tumors.*

GX

Histological Grade
Grade cannot be assessed

G1

Well differentiated

G2

Moderately Differentiated

G3

Poorly Differentiated

G4

Undifferentiated

*Information adapted from the National Cancer Institute (2014)

HNSCC may develop from precursor lesions (dysplasia), and in oral cancer these
precursor lesions are called leukoplakia. Areas of keratosis in the oral cavity are typically white
and can be classified into different grades (Figure 2.1). If untreated these pre-neoplastic lesions
develop into squamocellular carcinoma (Figure 2.2).
HNSCC is also separated into different stages of diseases. The most common staging
system used to grade head and neck cancers is the tumor node metastasis (TNM) classification
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system. The TNM classification system is a cancer staging system that helps describe the extent
and severity of a patient’s cancer [75]. General TNM staging for head and neck cancer is
described in Table 2.2 and is further broken down in Table 2.3. In regards to HNSCC, T
classifications are site specific and indicate the extent of the primary tumor, however there is
overlap between the various head and neck regions when considering cervical node (N)
classification [66].

Figure 2.1 Preneoplastic lesions in the oral cavity.
The images depict four different stages of leukoplakia. Images are
from the personal collection of P.P Claudio, M.D., Ph.D.
.
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Figure 2.2 Presentation of preneoplastic
lesions that have transformed into
squamocellular carcinoma.
(A) Ulcerative carcinoma (B) Exophytic
carcinoma. (C) Verrucous carcinoma. Images
are from the personal collection of P.P
Claudio, M.D., Ph.D.
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Table 2.1 TNM Classification used in HNSCC. *
TNM Classification
T

Describes the size of the primary tumor and
the extent to which it has invaded nearby
tissue

N

Describes whether regional lymph nodes are
involved

M

Describes if the cancer has spread from one
part of the body to another

*Information adapted from the National Cancer Institute (2014)

Table 2.2 General TNM staging of HNSCC. *
TNM Staging System

Primary Tumor (T)

Regional Lymph Nodes (N)

Distant Metastasis (M)

Staging

Description

TX

Primary tumor cannot be evaluated

T0

No evidence of primary tumor

Tis

Carcinoma in situ

T1-T4

Size and/or extent of the primary tumor

NX

Regional lymph nodes cannot be evaluated

N0

No regional lymph node involvement

N1-N3

Degree of regional lymph node involvement

MX

Distant metastasis cannot be evaluated

M0

No distant metastasis

M1

Distant metastasis is present

*Information adapted from the National Cancer Institute (2014)
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Diagnosis and Treatment
Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission
tomography (PET) are techniques used, in addition to a physical exam, to diagnosis HNSCC
[74]. If a mass is identified, a biopsy or fine needle aspiration are performed to evaluate whether
the tumor is benign or malignant. These examination techniques are effective in identifying
HNSCC, but unfortunately the initial symptoms of HNSCC are ambiguous and often overlooked
[66]. Therefore, the first indication that a patient has head and neck cancer is usually after it has
undergone metastasis to a local or regional lymph node [66]. Metastasis significantly impacts
treatment and survival for HNSCC patients, and the most common metastatic sites are the lungs,
bone, and liver. Pulmonary metastasis accounts for 60% of distant metastasis, while bone and
liver metastasis account for 22% and 10% of distant metastasis, respectively [76]. HNSCC is
also associated with second primary malignancies, which commonly occur in other areas of head
and neck, as well as lung and esophagus [77].
After diagnosis, HNSCC treatment plans depend on the patient’s age, location of the
tumor, stage of the cancer, and general health of the patient [66,76]. A large portion of patients
presenting with stage I or stage II HNSCC will be disease free after a single modality treatment
[76]. However, a majority of patients present with advanced HNSCC and require multi-modality
therapy to treat their disease [74,76]. Multi-modality therapy combines surgery, radiation, and/or
chemotherapy, and a description of each of these treatments is available in Table 2.3. Multimodality therapy is currently the best treatment approach for advanced disease due to the delicate
nature of the head and neck region. This treatment approach helps minimize the concentration
and dosage of any one therapy and also allows clinicians to preserve some function of affected
tissue after surgery [76]. Minimizing dosage and exposure to anti-cancer therapy is important
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because the oral cavity is highly susceptible to direct and indirect effects of chemotherapy and
ionizing radiation.
An additional factor that has a significant impact on a patient’s treatment is whether they
test positive for HPV. Patients with HPV-positive oropharyngeal cancers are treated differently
from their HPV negative counterparts [72]. Additionally, HPV-positive patients have a better
prognosis and respond to less intense therapy, compared to HPV-negative patients. The current
standard of treatment for HPV-positive tumors is cetuximab combined with radiation therapy.
Cetuximab is a monoclonal antibody (MAb) that represents an example of targeted
therapy. Cetuximab inhibits the Epidermal Growth Factor Receptor (EGFR), which is often
overexpressed in HNSCC. The goal of most targeted therapy is to identify biomarkers specific
to HNSCC, and use this knowledge to create personalized therapies [78]. This new area of
HNSCC research designs treatments that are to stimulate the immune system or control growth
of cancer. In addition to the previously mentioned Cetuximab, targeted molecular therapies
include other MAb, vaccines, and viruses, , [78,79]. These therapies are suggested to promote a
more favorable outcome with less systemic side effects.
The poor outcome for advanced HNSCC opens the door for other alternative therapies.
Nutritional compounds are new methods being explored in HNSCC therapy. These alternative
interventions can be systemically or locally applied and can be used as adjuvants to traditional
therapy. BITC is one form of adjuvant therapy being investigated for HNSCC and the effects of
this compound on HNSCC will be highlighted in Chapter 3 and 4.
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Table 2.3 HNSCC treatment options.*
Therapy type
Surgery

HNSCC Treatment Options
Description of therapy
Allows for removal of primary tumor and some metastatic regions.
Techniques include surgical resection and flap reconstruction.
Common therapy at all stages.

Radiation therapy

Uses high-energy x-rays or others type of radiation sources to
prevent cancer cells from growing. External and internal radiation
is both used to treat HNSCC. External radiation uses a machine
outside of the body to send radiation to tumor. Internal radiation
uses radioactive substances sealed in needles, seeds, wires, or
catheters that are placed directly into or near the cancer. Use of
radiation depends on stage and grade of tumor.

Chemotherapy

Anti-cancer agents administered systemically or regionally to stop
the growth of cancer cells, by killing them or preventing them
from dividing. According to the National Cancer Institute (2014)
there are seven chemo drugs approved by the FDA to treat head
and neck cancer: Cisplatin, Carboplatin, Methotrexate,
Fluorouracil, Bleomycin, Cetuximab, and Docetaxel. Use of
chemotherapy depends on stage and grade of tumor.

*Information obtained from Up-to-Date (2014)
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Pitfalls of Current Treatments
The most notable pitfall associated with HNSCC treatment is that the overall survival of
patients has not improved over the last three decades. Currently, the National Cancer Institute
(2014) suggests that the overall five-year survival rate for HNSCC is 40-50%, and this
percentage is significantly lower if a patient develops metastasis or secondary tumor in the head
and neck region. Around 60% of patients are diagnosed with locoregionally-advanced disease,
and treatment of advanced HNSCC is aggressive, with significant acute and long-term effects
[64]. Even with aggressive multi-modality therapy the five-year survival rate of locally
advanced disease is only 30% [67]. Furthermore, the “standard of care chemotherapy” for
advanced HNSCC disease only increases the five-year survival by 5% according to the MetaAnalysis for Chemotherapy of Head and Neck Cancer collaborative group [67].
On occasion, for loco-regionally advanced disease, a composite resection may be
indicated for patients with primary tumors that entail extensive soft tissue disease around the
mandible, thus requiring the need to sacrifice an intervening segment of mandible to accomplish
an in-continuity resection of the primary tumor in conjunction with neck dissection. These
particular operations are called “commando operation” or a composite resection that entail
excision of the intraoral primary tumor along with a segment of the intervening mandible
performed in conjunction with ipsilateral neck dissection as a monobloc surgical resection
(Figure 2.3).
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Figure 2.3 Presentation of locally advanced squamous cell carcinoma.

(A) Locally advanced oral pavement squamous cell carcinoma infiltrating the
gingiva and the mandibular symphysis. (B and C) Patient undergoing a
“commando operation” in conjunction with a bilateral neck dissection. D) Post
operative specimen: oral pavement squamous cell carcinoma along with part of the
tongue, a segment of the intervening mandible, and the bilateral neck lymph nodal
dissection. Images are from the personal collection of P.P Claudio, M.D., Ph.D.
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The aggressive nature of HNSCC and its delicate location makes it difficult to treat with
a single modality therapy. A multi-modality approach is associated with the highest success rate
for HNSCC, but often results in dramatic morphologic changes and increases in the
inflammatory response [78]. The inflammatory changes can increase edema and fibrosis, which
have significant impacts on a patient’s health. Complications with eating, speaking, and
breathing are additional effects commonly associated with both therapy and disease [78].
Chemotherapy and ionizing radiation also have a significant impact on the oral tissue and
the gastrointestinal tract. The cell turnover in the oral mucosa and the lining of the
gastrointestinal tract is rapid and leaves these areas very vulnerable to toxicity. The most
common oral complications related to cancer therapies are mucositis, infection, salivary gland
dysfunction, taste dysfunction, pain, and bleeding. Secondary complications can arise due to
these side-effects and lead to dehydration, dysgeusia, and malnutrition [67]. The primary and
secondary side-effects of treatment can inhibit optimal cancer therapy because a dose reduction
and/or modification of the treatment schedule are needed.
Lastly, reoccurrence after treatment of HNSCC is high. If reoccurrence or distant
metastasis occurs patients have a poor prognosis with a median survival rate of 6-10 months
[80]. Recurrent tumors are also resistant or unresponsive to many of the initial therapies used
treat HNSCC.
In conclusion, current therapy for stage I and stage II HNSCC is associated with high
survival. However, patients with stage III and stage IV are provided a poor prognosis, and the
therapy available has significant impacts on quality of life. Development of new therapies is
needed to increase survival and improve health of patients with HNSCC. Investigation of
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alternative treatment approaches, such as the administration of ITCs, could enhance the treatment
of HNSCC without the detrimental side effects.

Molecular Mechanisms of HNSCC
This section will highlight the most frequently altered molecular pathways in HNSCC.
Understanding the molecular and genetic alterations associated with HNSCC development will
help uncover mechanisms involved in tumor formation and identify potential targets for
improved therapy. Molecular techniques have already identified several tumor suppressor genes
and proto-oncogenes linked to HNSCC development. Loss of heterozygosity (LOH) studies
indicate that the earliest altercations appear in 3p (p16), 9p21 (CDKN2A1), and 17p13 (TP53).
At later stages in tumor formation, deletions of 4q, 6p, 13q and 14q and amplication of 7p and
11q are reported [80,81].
Early events in HNSCC carcinogenesis are linked to inactivation of p16. Inactivation of
p16 can be caused by LOH of 3p, homozygous deletion, point mutations, or promoter
hypermethylation [81]. Loss of the p16 gene results in deregulation of both the p53 and pRB,
and ultimately leads to uncontrolled proliferation [82]. Interestingly, instead of a p16 loss, HPV
positive tumors have an overexpression of p16 in the nucleus and cytoplasm [80]. Therefore,
p16 positivity is a reliable method for identifying HPV-positive tumors.
Around 70-80% of HNSCC cases have a loss of 9p21 (CDKN2A1) [81]. CDKN2A1 is a
growth suppressor and novel cell cycle regulator. CDKN2A1 promotes cell cycle arrest by
regulating the S phase of the cell cycle. TGFβ1 transcriptionally-induces CDK2AP1 expression,
and this in turn mediates the growth inhibitory activity of TGFβ1 by interacting with Cdk2 and
inhibiting pRb phosphorylation [80].
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Approximately 60% of HNSCC’s harbor a TP53 mutation [81]. p53 is described as the
“guardian of the genome” and is an important regulator of the cell cycle. Studies report that
alterations in p53 occur at a higher frequency in invasive carcinomas, compared to noninvasive
carcinomas [82].
EGFR is overexpressed in most HNSCC cases [81]. EGFR activation regulates multiple
pathways including: MAPK, Akt, ERK and the Jak/STAT pathway [81,83]. These pathways
regulate cellular proliferation, apoptosis, and metastasis. Dysfunction of EGFR and its
associated pathways occur in 80-90% of HNSCC cases [83].

Models used to study HNSCC
Cell Culture

HNSCC is a unique cancer because it includes a variety of different regions within the
head and neck area. The diversity in tumor location can make designing in vitro models
complicated, but many types of HNSCC develop from similar gene mutations. A more
confounding factor than tumor location when selecting a cell culture model is the presence or
absence of HPV, because HPV-positive cell lines respond differently to treatment compared to
HPV-negative cell lines. HPV-negative tumors still account for around ~80% of all HNSCC
cases. Therefore, in our studies we chose to focus on HPV-negative cell lines that represent the
oropharangeal region. A model using the HN30 and HN12 cell lines was developed by George
Yoo et al. (2000) [84]. This model was based on the observation that a p16 mutation is an early
mutation in HNSCC development (HN30) and a p53 mutation occurs at a greater frequency at
later stages and in invasive carcinomas (HN12) [84]. The cell lines used for in our studies are
described in Table 2.4.
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We also selected HN30, HN8, and HN12 because these cell lines represents three grades
of migration potential. The HN30 cell line does not migrate, while HN8 and HN12 cell lines
represent moderate and high migration, respectively. Selecting HN12 and HN8 cell lines for cell
culture experiments have additional benefits that could be utilized in the future studies. HN12
and HN8 are synchronous lymph node metastases and primary tumor cell lines are available
from the same patient.
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Table 2.4 Characterization of HAK, HN12, HN30 and HN8 cell lines.
NFκB

Cell Line*

Origin/Type

p53

p16

Tumorigenic

Vimentin

Migration
Capabilities

HAK

Normal Adult
Keratinocytes

WTa

WT

No

Normal

-

None

HN30

Pharynx

WT

Delc

Yes

Constitutively
active

+; only
when
grown in
matrigel

Low

HN12

Lymph node
metastasis
from the
tongue

Mutb

Delc

Yes

Constitutively
active

+

High

HN8

Lymph node
metastasis
from primary
oral tumor

Mutb

-

Yes

Constitutively
active

Unknown

Moderate

*All cell lines are HPV negative; aWT=wild-type; bMut=mutated; cdel=deleted

Animal Models

There are several animal models used to study HNSCC. Models that use chemical
carcinogens to induce tumor formation are ideal in HNSCC prevention studies. The most
frequently used inducers are 9,10-dimethyl-1,2-benzanthracene (DMBA) and 4-nitroquinoline-1oxide (4NQO) [81]. The carcinogen 4NQO can be administered through drinking water or via
local application. Application of 4NQO replicates the human disease from preneoplasitc lesion
to tumor. Additionally, this model activates oncogenes, including H-Ras (an EGFR), and is
associated with spontaneous mutations in the tumor suppressor, p53, both of which are
associated with HNSCC development [81].
No one particular xenograft model mimics HNSCC progression as is it observed in
humans. Currently, the best animal model to mimic human disease progression is an orthotropic
HNSCC model [85]. This model requires injection of exponentially growing HNSCC cells into
the tongue of athymic nude mice. This model is associated with lymph node and regional
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metastasis to the lung, however the percentage of mice that present with these forms of
metastasis is inconsistent [85]. Plus, identifying lymph node metastasis is difficult.
Furthermore, the time it takes to grow the tumors in the tongue is longer than most xenograft
models. Also, these mice are reported to have problems eating and lose weight making feeding
studies difficult.
In another model of HNSCC, exponentially growing HNSCC cells are being
subcutaneously injected into the hindlimb of athymic mice [85]. It is easier to measure tumor
formation with this model, than with the orthotropic model. This model is also acceptable for
feeding or intravenous treatments. However, this model is not ideal to study metastasis.
Advancements are being made in techniques to monitor metastasis and this will greatly
improve HNSCC animal models.
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ABSTRACT
Metastasis and chemoresistance represent two detrimental events that greatly hinder the
outcome for those suffering with head and neck squamous cell carcinoma (HNSCC). Herein, we
investigated benzyl isothiocyanate’s (BITC) ability to inhibit HNSCC migration and invasion
and enhance chemotherapy. Our data suggests that treatment with BITC: 1) induced significant
reductions in the viability of multiple HNSCC cell lines tested (HN12, HN8, and HN30) after 24
and 48 hours, 2) decreased migration and invasion of the HN12 cells in a dose dependent
manner, and 3) inhibited expression and altered localization of the epithelial-mesenchymal
transition (EMT) marker, vimentin. We also observed that a pretreatment of BITC followed by
treatment of cisplatin: 1) induced a greater decrease in HN12, HN30, and HN8 cell viability and
proliferation compared to either treatment alone, and 2) significantly increased apoptosis when
compared to either treatment alone. Taken together these data suggest that BITC has the
capacity to inhibit processes involved in metastasis and enhance the effectiveness of
chemotherapy. Consequently, the results indicate that further investigation, including in vivo
studies, are warranted.

Keywords: Head and Neck Squamous Cell Carcinoma, isothiocyanate, BITC, migration,
invasion, EMT, vimentin
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common form of
cancer worldwide, and the 8th leading cause of cancer-related deaths [86]. Current treatment for
HNSCC often entails a disfiguring and risky surgical operation, combined with chemotherapy
and/or radiation therapy [87-89]. These treatment options are associated with numerous side
effects that dramatically affect a patient’s quality of life, and despite the aggressive treatment
options the increase in overall survival of HNSCC has not improved in the past three decades
[86,89-92]. The low survival rate is due, in part, to both loco-regional and distant metastasis,
which occurs in 40-60 percent of HNSCC patients [89,92,93]. Additionally, the rate of HNSCC
metastasis after recurrence is high, and relapse/recurrence is associated with heightened
chemoresistance [92].
A common chemotherapeutic drug used for HNSCC is cisplatin, but the side effects
associated with effective treatment doses can be severe. Additionally, one of the major obstacles
in the therapeutic use of cisplatin is intrinsic or acquired resistance. Therefore, adjuvants
therapies that enhance the efficacy of cisplatin and/or decrease the amount of cisplatin needed to
achieve tumor response could improve patient outcome.
The acquisition of chemoresistance and the initiation of metastasis are complex multistep processes. The use of natural products, such as isothiocyanates (ITCs), which are known to
target many cellular pathways linked to both of these processes, provides a unique therapy option
for HNSCC. ITCs are phytochemicals produced by several plant species, particularly
cruciferous vegetables [6,49]. ITCs are a product of glucosinolate hydrolysis, which is initiated
by an enzyme called myrosinase [2]. This enzyme is found spatially separated from
glucosinolates in cruciferous vegetables and in our own human enteric microflora [2]. The
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reactive group of ITCs, R-N=C=S, plays a significant role in ITCs involvement in numerous
cellular pathways [4]. This functional group is known to target cysteine residues, which are
often found in the catalytic site of many enzymes, and thereby can induce a wide range of effects
inside a cell [7,8].
Benzyl isothiocyanate (BITC) is an ITC of particular interest in cancer therapy because
of its ability to inhibit cell growth and induce apoptosis in several types of cancer cell lines,
including HNSCC [2,25,94]. In addition to inhibiting cell growth and inducing apoptosis, BITC
may play a role in inhibiting angiogenesis, epithelial-mesenchymal transition (EMT), and
metastasis [13,40,95].
The present study builds on recent findings, which indicate that BITC may be able to
inhibit metastasis and increase chemosensitivity. The evidence suggests that ITCs may prevent
migration and invasion of several types of cancer cells, but the role of BITC in prevention of
HNSCC migration and invasion has not been investigated. We elected to focus on BITC over
other ITCs because our preliminary screenings suggested that the concentrations needed to elicit
a response in HNSCC appear to be lower than other ITCs studied. Through the use of various in
vitro studies we are reporting for the first time that BITC can inhibit migration and invasion of
HNSCC cell lines. The potential use of BITC as an adjuvant treatment to inhibit metastasis,
decrease markers associated with EMT, and enhance chemotherapy is a novel treatment
approach.

40

MATERIALS AND METHODS
Materials
Benzyl isothiocyanate (99.5% pure) was purchased from LKT Laboratories, Inc. (St.
Paul, MN). Stock solutions of BITC (100mM) were prepared in DMSO and diluted into growth
medium such that the final concentration of DMSO did not exceed 0.02% (vol./vol.), a
concentration that did not induce toxicity in HN12, HN30, HN8, and HAK cells. CisDiammineplatinum (II) dichloride (CDDP) was purchased from Sigma-Aldrich (St. Louis, MO).
Stock concentrations of CDDP (1mg/1mL) were prepared in a 0.9% sterile saline solution.

Cell Culture and Reagents
The highly metastatic HNSCC cell line, HN12, and moderately metastatic HNSCC cell
line, HN30, were a kind gift from Dr. George Yoo (Karmanos Cancer Center, Wayne State
University, OH) [91]. The HN8 cell line was a gift from Dr. J. Silvio Gutkind (NIH, Bethesda,
MD) [96]. The normal human adult keratinocyte cell line, HAK, was obtained from Zen-Bio,
Inc. (Research Triangle Park, NC). Monolayer cultures of HN12, HN30 and HN8 were
maintained in DMEM (HyClone, Thermo-Scientific) adjusted to contain 10% fetal bovine serum
(FBS) (PAA Laboratories GmbH, Pasching, Austria) and supplemented with 1% (vol./vol.)
penicillin-streptomycin (P/S) (Corning Cellgro, Manassas, VA). HAK cells were maintained in
Adult Keratinocyte Growth Medium (KM-2) (Zen-Bio, Research Triangle Park, NC). Cells
were grown in a humidified incubator at 37oC and with 5% CO2.
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MTT Cell Viability Assay
HN12, HN8, and HN30 cells were seeded at an initial density of 5x103 cells/well and
HAK cells were seeded at an initial density of 15x103 cells/well in 96-well tissue culture plates
(Corning, Corning, NY) and allowed to settle overnight. The seeding density was selected so
that all cell lines had a similar confluence after 24 hours. Cells were subsequently treated with
1.25-10M BITC for 1-hour. After 1-hour plates were washed and media was replaced with
fresh DMEM. The cell viability was determined after 24- and 48-hours using thiazolyl blue
tetrazolium bromide (Sigma-Aldrich, St. Louis, MO). Cells were incubated with dye for 2 hours,
and then media was removed and replaced with DMSO. Color development in the plates was
read at 590nm using the SpectraMax M2e plate reader (Molecular Devices, Sunnyvale, CA). The
intensity of the color is correlated with the metabolic activity of living cells.

Wound Healing Assay
Cell migration was determined using wound healing assay. HN12 cells were cultured in
DMEM (10% FBS, 1% Pen-Strep) in 6-well plates until 90% confluent, and then media was
changed to DMEM with 0.05% FBS, 1% P/S overnight to synchronize the cells. A permanent
line was drawn horizontally on the bottom of each well, and a plastic pipette tip was used to
generate 3 vertical scratches per well. Cell debris was washed away with PBS and initial scratch
sizes were determined with an inverted light microscope (Olympus IX51, Center Valley, PA) at
100X magnification. Six measurements were made per well, 1 below and 1 above the horizontal
line for each scratch before treatment. Cells were treated with 2.5-5M BITC for 1-hour at
37oC. DMSO, at the same concentration as in the BITC treated wells, was used for the vehicle
control. After 1-hour plates were washed with PBS and treatment was replaced with DMEM
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(10% FBS, 1% P/S). Wound healing was analyzed 24 hours after treatment. Images were taken
at 100X magnification, as described above, and changes in cell migration were determined by
calculating the percent of wound healing. Percent wound healing= ([scatcht-0hr - scatcht24hr]/scatcht-0hr)*100.

Experiments were repeated 3 times.

Invasion Assay
The effect of BITC on invasion of HN12 cells was determined using Invasion Chambers
with 8μm pores (BD Biocoat, Franklin Lakes, NJ). Polycarbonate membranes on the bottom of
the Boyden chamber inserts were rehydrated following manufacturer’s instructions and 0.5mL of
HNSCC cell suspension containing 5x104 cells was added to each insert. Cells were allowed to
attach for 4 hours prior to treatment in complete DMEM media (10% FBS, 1%P/S). After
attachment the appropriate wells were treated for 1-hour with BITC (2.5-5μM) in serum free
DMEM. Epidermal growth factor (EGF) was used at (10ng/1mL in serum free DMEM (0.5%
BSA, 1% P/S)) was added to the bottom well in all wells, except for the negative control, as a
chemoattractant. Media in all inserts was replaced after 1-hour with DMEM (0.5% BSA, 1%
P/S). Analysis of cell invasion was performed 24 hours after beginning treatment. Media and
cells were removed from the top of the matrigel following manufactures’ instructions and cells
were fixed with 100% methanol, washed with PBS, and stained with 0.1% Crystal Violet. Cells
counts were performed and images taken using an Olympus IX51 inverted light microscope
(Olympus, Center Valley, PA) at 400X magnification. Twenty fields of view were counted for
each sample and averaged to determine the mean number of cells/field of view. Experiments
were repeated a minimum of 3 times.
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Western Blot Analysis
Vimentin and bcl-2 expression were analyzed 24 hours after BITC treatment in HNSCC
cells. Cell pellets were lysed with RIPA buffer (1% NP-40, 0.1% SDS, 50mM Tris-HCl pH 7.4,
150mM NaCl, 0.5% Sodium Deoxycholate, 1mM EDTA) for analysis. Densitometry was
calculated using α-actin (SantaCruz, Santa Crutz, CA) as a loading control for all Western blots.
Vimentin antibody (AVIVA, San Diego, CA) was used at a 1:1000 dilution in a 5%
milk/TBST buffer. Horseradish peroxidase-conjugated goat anti-rabbit secondary antibody
(Rockland, Gilbertsville, PA) was used (1:10,000). The signal was developed with ECL Prime
western blotting detection reagent (Amersham, Piscataway, NJ).
Bcl-2 antibody (SantaCruz, Santa Crutz, CA) was used at a 1:1000 dilution in a 5%
milk/TBST buffer. Horseradish peroxidase-conjugated goat anti-mouse secondary antibody
(Rockland, Gilbertsville, PA) was used (1:5,000). The signal was developed with ECL Prime
Western blotting detection reagent (Amersham, Piscataway, NJ).

Indirect Immunofluorescence
HN12 cells were seeded initially at a density of 4x104 in Nunc Lab Tek II
immunofluorescence chambers (Fisher Scientifics, Pittsburgh, PA). Cells were allowed to attach
overnight before treatment with BITC (5-10μM) for 1-hour. Treatment media was then
removed and replaced with complete DMEM (10%FBS, 1%P/S). Twenty-four hours after
treatment, cells were fixed with 4% paraformaldehyde and permeabilized in PBS containing 1%
BSA and 0.1% Triton X-100. Cells were blocked with PBS/1% BSA prior to staining. Vimentin
(AVIVA, San Diego, CA) was diluted 1:400 with PBS containing 1% BSA and appropriate wells
were incubated with primary antibody in a dark humidified chamber for 1-hour. Cells were then
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washed and incubated with Alexa Fluor 488 (Invitrogen, Grand Island, NY) secondary antibody
(1:200) in humid and dark conditions for 45 minutes. Slides were detached from
immunofluorescence chambers and Vectashield mounting media with DAPI (Vector
Laboratories, Burlingame, CA) was added to slides before analysis. Images taken using an
Olympus IX51 inverted microscope equipped with epifluorescence (Olympus, Center Valley,
PA).

MTT Cell Viability/Chemosensitivity Assay
HN12, HN8, and HN30 cells were seeded at an initial density of 5x103 cells/well in
Corning 96-well tissue culture plates (Corning, NY) and allowed to settle overnight. Cells were
then treated with 2.5-10M BITC for 1-hour, 5-10M of CDDP for 24 hours, or a 1-hour
pretreatment of 2.5-10M BITC followed by a treatment of 5-10M of CDDP for 24 hours.
Media was changed in all wells 24 hours after cisplatin treatment prior to the 48-hour analysis.
Cell viability was determined 24 or 48 hours later as described above under MTT Cell
Proliferation/Viability Assay methods. Results were performed in technical quadruplets with
three biological replicates.

Trypan Blue Dead/Live Assay
HN12, HN8, and HN30 cells were seeded at an initial density of 3x105 cells/well in
Corning 6-well tissue culture plates (Corning, NY) and allowed to settle overnight. Cells were
then treated with 5-10M BITC for 1-hour, or 10M of CDDP for 24 hours, or a 1-hour
pretreatment with 5-10M BITC followed by 10M of CDDP for 24 hours. Cell counts were
performed 24 and 48 hours after initiating CDDP treatment. Cells were trypsinized and washed
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in PBS prior to cell count. Cells in each treatment group were mixed 1:1 with a trypan blue
solution (0.4% trypan blue in PBS) and counted using a hemacytometer.

Annexin-V/PI Assay
HN12 and HN30 cells were seeded at an initial density of 2x106 cells in 10cm Corning
tissue culture dish (Corning, NY) and allowed to settle overnight. Cells were treated as
described above in the Dead/Live assay methods. Treatment-induced cell death was determined
by flow cytometry using an Annexin-V assay kit (eBiosciences, San Diego, CA). 24 and 48
hours after initiating CDDP treatment cells were collected and 1x106 cells per group were
subjected to a double staining with an Annexin-V-FITC antibody and Propidium Iodide
following the manufacturer’s instructions. Cells were analyzed using an Accuri C6 Flow
Cytometer (BD Accuri, San Jose, CA). Early apoptosis was defined as cells positive for
Annexin-V-FITC only. Late apoptosis was defined as cells positive for Annexin-V-FITC and
Propidium Iodide (PI). Necrosis was defined as cells positive for PI only

Statistical Analysis
All experiments were performed at least three times as independent experiments.
Statistical analyses were done with a multiple comparison test with appropriate post-hoc test.
GraphPad Prism (La Jolla, CA) was used for all statistical analysis. A p-value of <0.05 was
considered statistically significant.
The combination index of BITC and cisplatin combination was analyzed using the
following equation: CI=(CA,X/ICX,A) + (CB,X/ICX,B) as described in Zhao et al. (2010) [97]. In
this equation CI is the combination index; CA,X and CB,X are the concentration of drugs A and B

46

used in a combination that generates x% of the maximal combination effect; ICx is the drug
concentration needed to produce x% of the maximal effect. A CI of less than, equal to, and more
than 1 indicates synergy, additivity, and antagonism, respectively.
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RESULTS
BITC Decreased the Cell Viability of Three HNSCC Cell Lines
MTT assay results indicate that a 1-hour treatment of 10μM BITC significantly decreased
the cell viability (p≤0.05) of the HN12, HN8 and HN30 cell lines after 24 and 48 hours (Fig 3.1
A and B). However, a 1-hour treatment of 2.5-5μM BITC did not significantly affect the cell
viability of these HNSCC cell lines after 24 hours, and at 48 hours a significant decrease in cell
viability was only observed in the HN30 cell line after a 5μM BITC treatment (Figure 3.1 A and
B). Treatment of the normal keratinocyte cell line (HAK) with 2.5-10μM BITC did not decrease
cell viability (Figure 3.1 A and B). Thus, BITC has selective toxicity for HNSCC cancer cells.
A 1-hour treatment was selected for future experiments because the cell viability of HNSCC
cells was not significantly different whether treated with 2.5-10μM BITC for 1, 16, or 24 hours
(data not shown).
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Figure 3.1 HNSCC percent viability measured by MTT assay following
exposure to BITC treatments.
(A) Percent viability of HAK, HN12, HN30 and HN8 cells at 24 hours. (B)
Percent viability of HAK, HN12, HN30 and HN8 cells at 48 hours. (*)indicates
significant difference from respective cell line vehicle control. Percent viability
was assessed by comparing treatment values to negative control. Error bars
represent standard deviation. One-way ANOVA for multiple comparisons with
Dunnet’s Post-Hoc test (*p≤0.05).
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BITC Inhibited Migration and Invasion of HNSCC Cells
A wound-healing assay indicated that BITC inhibits migration of the highly metastatic
HN12 cells in a dose dependent manner. After 24 hours, inhibition of cellular migration was
observed in the highly metastatic HN12 cell line when using a 2.5µM BITC treatment, however
a significant decrease in wound healing required 5µM BITC (p≤0.05) (Figure 3.2 A and B).
Similar results were observed when using the HN8 cell line, but not the HN30 cell line (data not
shown). Although, it should be noted that the HN30 cell line did not undergo “wound-healing”
under control conditions.
The ability of BITC to inhibit the migration of HN12 cells prompted us to investigate the
effect of BITC on invasion through Matrigel. Figure 3.3 (panels A and B) depict that 1-hour
treatment of BITC significantly inhibited the invasion of HN12 cells (p≤0.05). Compared to the
vehicle control the average number of invading cells per field of view decreased by 52.34% after
a 2.5μM BITC treatment and 90.96% after a 5μM BITC treatment (p≤0.05). Viability assays
confirmed that the addition of the chemo-attractant, EGF, to the cells did not change the viability
and proliferation of HNSCC cells after BITC treatment (data not shown). These results
substantiate the wound-healing assay data and indicate that BITC targets both migration and
invasion of certain HNSCC cell lines.
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Figure 3.2 BITC inhibited wound-healing of the HN12 cell line after 24 hours.
(A) Inverted light microscope images of HN12 cells 24 hours after a 1-hour BITC treatment (2.55µM). Dashed lines represent scratch size before treatment. Vehicle control was DMSO.
Magnification 100X. (B) Bar diagram represents the percent wound healing determined after 24
hours using wound size measurements. Error bars represent standard deviation. One-way ANOVA
for multiple comparisons with Dunnet’s Post-Hoc test (*p≤0.05). Neg: negative control. Veh: vehicle
control.
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Figure 3.3 BITC treatment inhibited
invasion of the HN12 cell line after 24
hours.
(A) Bar diagram represents the average
number of invading cells/field of view
counted at 24 hours following a 1-hour
treatment of HN12 cells with BITC.
EGF was used as chemoattractant. Error
bars represent standard deviation. Oneway ANOVA for multiple comparisons
with Dunnet’s Post-Hoc test (*p≤0.05).
(B) Inverted light microscope pictures of
HN12 cells stained with crystal violet
following BITC treatment.
Magnification 200X. .Neg: negative
control. Veh: vehicle control.
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Vimentin Expression Decreased after BITC Treatment
Vimentin is an intermediate filament protein associated with EMT and HNSCC cell
invasion [98,99]. We determined BITC treatment alters vimentin expression or localization. We
observed that vimentin expression was inhibited 24 hours after a 1-hour BITC treatment (2.510μM), in a dose dependent manner (Figure 3.4 A). The localization of vimentin also appeared
altered after BITC treatment. In the vehicle control vimentin was evenly dispersed, and was also
observed in cellular projections. However, after BITC treatment these projections disappeared,
and vimentin was observed as aggregates inside the cells. Our immunofluorescence results are
supported by Western blot analysis showing a significant decrease in vimentin expression
occurred after a 24 hour BITC treatment of 5 and 10μM (p≤0.05) (Figure 3.4 B and C).
Although the treatment conditions changed for the Western blot analysis, cellular viability of
HNSCC cells did not change whether treated with BITC for 1, 16, or 24 hours (data not shown).
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Figure 3.4 Vimentin expression in
the HN12 cell line decreased
following BITC treatment.
(A) Representative
immunofluorescence images of a
vimentin immunostaining in HN12
cells acquired with an inverted
epifluorescence microscope 24 hours
after a 1-hour treatment with a range
of concentrations of BITC (5-10µM).
Anti-vimentin (1:400); AbII antirabbit Alexa Fluor 488 (1:200);
DAPI to counterstain the nuclei.
Magnification 400X. Bar size is
10µm. (B) Western blot analysis of
vimentin expression in HN12 cells
24 hours after a 1-hour treatment
with a range of concentrations of
BITC (1.25-10µM). Actin was used
to normalize the blot. (C)
Densitometric analysis of vimentin
and actin protein expression.
Diagram represents the fold change
of vimentin after 24 hours
normalized to actin control. Ctrl:
negative control. Veh: vehicle
control. One-way ANOVA for
multiple comparisons with Dunnett’s
Post-Hoc test (*p≤0.05).
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Pretreatment with BITC Followed by Cisplatin Decreased HNSCC Cell Viability and
Enhanced Cell Death
One of the major obstacles in the therapeutic use of platinum analogues is intrinsic or
acquired resistance [100-103]. The high cisplatin resistance observed in our HNSCC cell lines
prompted us to investigate whether BITC treatment of HNSCC cells enhances their response to
CDDP.
A 1-hour pretreatment of BITC enhanced the effect of CDDP after 24 and 48 hours,
compared to either BITC or CDDP treatment alone (p≤0.05) (Figure 3.5 A-C). The strongest
decrease in cell viability was observed at 48 hours when the HNSSC cells were pretreated with
10µM BITC followed by 10µM CDDP treatment (Combination index CI= 0.52 to 0.93)
(p≤0.0001) (Figure 3.5 A-C). Combination of 10µM BITC and 10µM cisplatin showed a
synergistic effect in HN8 cells at 48 hours (CI= 0.73), but only additive effect at 24 hours (CI=
1.09).
A synergistic effect was also observed at 24 and 48 hours in HN30 (24 hours CI= 0.79;
48 hours CI= 0.52) and HN12 cells (24 hours CI= 0.86; 48 hours CI= 0.93) following a
combination treatment of 10µM BITC and 10µM cisplatin (Figure 3.5).
The MTT assay assesses changes in cell viability, however the MTT assay does not
differentiate between proliferation and/or cell death. Therefore, we used a trypan blue dead/live
assay and an Annexin-V assay (apoptosis) to determine if BITC pretreatment increased cell
death. The trypan blue dead/live assay (Figure 3.6 A, B, D, E, G, and H) indicated that cell
death was significantly enhanced by BITC pretreatment followed by CDPP in all three HNSCC
cells (HN8, HN12, and HN30), compared to treatment with either compound alone. However,
the most dramatic increase in cell death was observed when HN30 cells were pretreated for 1-
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hour with 10µM BITC followed by a 24-hour 10µM CDDP treatment, synergistic effect CI= 0.9;
p≤0.0001) (Figure 3.6 D). These results were verified by numerical cell counts at the 24 and 48
hour time points of the different treatment groups (Figure 3.6 C, F, and I).
An Annexin-V assay showed a significant increase in early and late apoptosis after a
pretreatment of 10µM BITC followed by 10µM CDPP in both the HN30 and HN12 cell lines
after 24 hours (p≤0.001) (Figure 3.7 A and B). Additionally, the total percent of dead cells
(early, late apoptosis, and necrosis) increased significantly when cells were pretreated for 1-hour
with 10µM BITC followed by a 24-hour 10µM CDDP treatment (p≤0.0001).
Together the results of the MTT assay, dead/live assay, cell counts, and Annexin-V assay
show that pretreatment of HNSCC cells with BITC followed by CDDP significantly increased
HNSCC cell death relative to either agent used as a single therapeutic.
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Figure 3.5 Dead/Live cell viability assay and cell counts of HNSCC cells following treatment
with BITC, CDDP, or a pretreatment of BITC followed by CDDP.
(A-B) Diagrams represent the percent of HN12 cells that were alive after 24 (A) and 48 (B) hours
following BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment. (C) Diagram
depicts cellular proliferation of HN12 cell line 24 and 48 hours after a BITC, CDDP, or a pretreatment
of BITC followed by a CDDP treatment. (D-E) Diagrams represent the percent of HN30 cells that
were alive after 24 (D) and 48 (E) hours following BITC, CDDP, or pretreatment of BITC followed
by a CDDP treatment. (F) Diagram depicts cellular proliferation of HN30 cell line 24 and 48 hours
after a 24 and 48 hours following BITC, CDDP, or a pretreatment of BITC followed by a CDDP
treatment. (G-H) Diagrams represent the percent of HN8 cells that were alive after 24 (G) and 48 (H)
hours following BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment. (I)
Diagram depicts cellular proliferation of HN8 cell line 24 and 48 hours after a BITC, CDDP, or a
pretreatment of BITC followed by a CDDP treatment. Control: negative control. Vehicle: vehicle
control. Cis: Cisplatin/CDDP. Error bars represent standard deviation. Error bars represent standard
deviation. One-way ANOVA for multiple comparisons with Dunnet’s Post-Hoc test (*p≤0.05;
**p≤0.001; ***p≤0.0001).
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Figure 3.6 MTT viability assay of HNSCC cells following treatment with BITC, CDDP, or a
combination of BITC followed by CDDP compared to controls.
(A) Diagram represents the percent of HN12 viable cells after 24 and 48 hours following BITC,
CDDP, or a pretreatment of BITC followed by a CDDP treatment (24 hours CI= 0.86; 48 hours
CI= 0.93). (B) Diagram represents the percent of HN30 viable cells after 24 and 48 hours
following BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment (24 hours CI=
0.79; 48 hours CI= 0.52). (C) Diagram represents the percent of HN8 viable cells after 24 and 48
hours following BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment (24
hours CI= 1.09; 48 hours CI= 0.73). Dark grey bars indicate cell viability at 24 hours; light grey
bars indicate cell viability at 48 hours. Ctrl: negative control. Veh B+C: vehicle control. B:
BITC. C: Cisplatin/CDDP. Error bars represent standard deviation. One-way ANOVA for
multiple comparisons with Dunnet’s Post-Hoc test (*p ≤ 0.05; **p ≤ 0.001; ***p≤0.0001).
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Figure 3.7 Annexin-V assay of HN12 and HN30 cells following treatment with BITC, CDDP, or
a pretreatment of BITC followed by CDDP.
(A) Bar diagram represents the percent of HN12 cells that are in early/late apoptosis or necrosis 24
hours after a BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment. (B) Bar
diagram represents the percent of HN12 cells that are in early/late apoptosis or necrosis 24 hours after
a BITC, CDDP, or a pretreatment of BITC followed by a CDDP treatment. Black bars represent
necrosis, white bars early apoptosis, and grey bars late apoptosis. Error bars represent standard error
of the mean. Ctrl: negative control. Veh: vehicle control. Cis: Cisplatin/CDDP. One-way ANOVA
for multiple comparisons with Dunnet’s Post-Hoc test (*p≤0.05; **p≤0.001; ***p≤0.0001).
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BITC Treatment Deceases the Expression of Anti-apoptotic Protein Bcl-2
Bcl-2 is an anti-apoptotic protein that is overexpressed in most cancer cells. Western blot
analysis indicates that a 1-hour BITC treatment reduces the expression of bcl-2 in the HN12 cell
line after 24 hours (Figure 3.8 A and B). A decrease in bcl-2 expression is observed after a
5µM BITC treatment, but the reduction in bcl-2 is not statistically significantly until after a
10µM BITC treatment (p≤0.05). A decrease in bcl-2 expression supports the annexin-V assay,
and indicates that BITC treatments increase apoptosis in HNSCC cell lines.
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Figure 3.8 Bcl-2 Expression decreased in the HN12 cell line 24 hours after BITC
treatment.
(A) Western blot analysis of bcl-2 expression in HN12 cells after a 1-hour treatment
with 5 or 10µM BITC. Actin was used to normalize the blot. (B) Densitometric
analysis of bcl-2 and actin protein expression. Diagram represents the relative
expression of bcl-2 after 24 hours normalized to actin control. Neg: negative control.
Veh B+C: vehicle control. B: BITC. Error bars represent standard deviation. Oneway ANOVA for multiple comparisons with Dunnett’s Post-Hoc test (*p≤0.05).
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DISCUSSION
The treatment for HNSCC often involves a disfiguring surgical operation and either prior
or subsequent chemotherapy and/or radiation therapy [86,104]. These combined treatment
modalities are often associated with side effects that reduce the patient’s quality of life. HNSCC
metastasis and chemoresistance are two of the leading reasons for this multimodal treatment
approach. The inability to effectively target these events, whether separately or together, leads to
a poor prognosis. Consequently, those who suffer from aggressive HNSCC face a debilitating
disease, and need improved therapeutic options.
ITCs are natural compounds exhibiting potent anti-tumor effects in both cell culture and
animal models [20,39,40,105]. In humans, ITCs are safe at clinically relevant concentrations and
have high oral bioavailability, making them promising adjuvant therapy tools for the treatment of
cancer [2,5,105]. Here, we show that BITC inhibits HNSCC cell migration and invasion, as
well as sensitizes HNSCC cells to the chemotherapeutic drug cisplatin at clinically relevant
concentrations [39,95]. Additionally, BITC decreased the expression of vimentin, a marker
associated with EMT, in the HN12 cell line.
Tumors are not homogenous and may have different aberrant pathways that contribute to
maintenance of cancer phenotype. The type of mutations present in different cancer cell could
play a significant role on the different pathways and molecular targets of BITC. Since BITC’s
targets appear to be multifactorial we decided to focus primarily on the end points of cell death,
proliferation, migration and invasion. Collectively our results illustrate that the effects of BITC,
in regards to migration/invasion and chemoenhancement (greater anti-neoplastic effect than the
sum of BITC or CDDP treatment alone) are not cell line specific. Importantly, BITC selectively
targeted the viability of HNSCC cells, but not normal keratinocytes (Figure 3.1).
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Vimentin expression in epithelial cells is a marker for epithelial-mesenchymal transition
(EMT). Vimentin's overexpression in HNSCC correlates well with accelerated tumor growth,
invasion, and poor prognosis [106]. Therefore, vimentin serves as an attractive potential target
for HNSCC therapy. Many EMT markers are correlated with poor HNSCC prognosis, but few
therapies have been shown to actually regulate the expression of these markers. Additionally,
EMT, directly or indirectly links HNSCC metastasis and chemoresistance. Our findings that
BITC treatment decreases vimentin expression in HNSCC cells suggest these cells are less likely
to undergo EMT following BITC exposure indicating a unique property of this phytochemical
that could be exploited for therapy.
Despite significant improvements in treatment modalities, long-term survival rates in
patients with advanced-stage HNSCC have not increased significantly in the past 30 years.
Radiation and chemotherapy are nonselective and can cause damage to normal tissue. Cisplatin
is one example of a non-selective drug commonly used to treat HNSCC. This drug is associated
with many detrimental side effects. Additionally, intrinsic or acquired resistance to platinum
analogues is a major obstacle in HNSCC therapy. The results of our MTT assay, dead/live
assay, cell counts, and Annexin-V assay support the use of BITC to either counteract cisplatin
resistance or enhance its activity (Figure 3.5 and Figure 3.6). The concentrations selected for
these studies mimic the peak plasma concentration of cisplatin [107,108].
In conclusion, our results show that BITC targets cell viability and reduces the amount of
migration and invasion of HNSCC cells, but not of normal keratinocytes. The inhibition of
migration and invasion we observed may be due to the ability of BITC to target key players
involved in EMT, such as vimentin. Additionally, pretreatment with BITC chemosensitized the
HNSCC cells to cisplatin by decreasing cell viability and increasing cell death suggesting that
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BITC could be a novel adjuvant therapy for patients with aggressive HNSCC. These initial
findings warrant future in vivo animal studies to ensure that BITC can reach tumor cells in
adequate concentrations to induce xenograft or organotypic human HNSCC tumors to undergo
the changes in viability and drug sensitivity that we have documented in cell culture.
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Chapter 4 : Benzyl Isothiocyanate Induced ROS Regulates HNSCC
Cell Migration and Viability

ABSTRACT
In comparison to non-malignant cells, cancerous cells tend to display elevated levels of
basal reactive oxygen species (ROS). As a consequence of the elevated levels of basal ROS,
cancer cells are highly dependent on antioxidant defense systems. Therapeutic agents that
abrogate or compromise the antioxidant system can leave cancer cells particularly vulnerable to
the cytotoxic effects of ROS. Head and neck squamous carcinoma (HNSCC) cells are sensitive
to treatments that alter the antioxidant system and induce ROS. Isothiocyanates (ITCs) are
known inducers of ROS. Using a dicholorofluorescein (DCF) assay, as a measure of
intracellular ROS, we demonstrate that the ITC, benzyl isothiocyanate (BITC), significantly
increased ROS production in the HN12 and HN30 HNSCC cell lines. The increase in ROS was
attenuated by the addition of antioxidants, N-acetyl-L-cysteine (NAC) and catalase. BITC, at
concentrations that did not affect HNSCC cell viability, prevented wound healing in the HN12
cell line. The addition of either NAC or catalase reversed the wound healing inhibitory effect of
BITC. NAC or catalase also prevented BITC-induced cytotoxicity in the HN12 and HN30 cell
lines. Additionally, NAC reduced the cytotoxic effects of the combinatorial treatment of BITC
and cisplatin. Collectively, these results suggest that ROS are important components in BITCs
ability to induce cytotoxicity and inhibit migration in HNSCC.

Keywords: Head and Neck Squamous Cell Carcinoma, isothiocyanate, BITC, migration,
reactive oxygen species, N-acetyl-L-cysteine, catalase
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INTRODUCTION

We have previously shown that benzyl isothiocyanate (BITC) treatment inhibits
migration and invasion and enhances the effects of the chemotherapeutic drug, cisplatin, in
HNSCC cell lines [44]. However, the mechanism through which BITC elicits its effects on
HNSCC cells remains unclear. In the present study, we investigated whether reactive oxygen
species (ROS) induction is a possible mechanism by which BITC can prevent migration and add
to the effectiveness of chemotherapy.
Malignant transformation often leads to an altered antioxidant system that promotes
cancer cell survival. Additionally, pathways effected by these alterations lead to resistance from
anti-cancer agents [44]. Manipulating the antioxidant system by altering the levels of glutathione
(GSH) and/or ROS can provide a biochemical basis to selectively kill cancer cells, while leaving
normal cells unaffected. Normal cells have low levels of basal ROS and the antioxidant system
is able to tolerate inductions of ROS [23,98,109]. However, in cancer cells, an increase in basal
ROS generation renders these cells highly dependent on the antioxidant system and agents that
abrogate or compromise this system can leave the cancer cells vulnerable [109,110].
Consequently, anti-cancer agents that manipulate the redox balance are effective in treating a
variety of cancers, including HNSCC [23,44,45,109,111].
Inducers of ROS are effective in triggering apoptosis in HNSCC cells thereby indicating
that agents like isothiocyanates (ITCs), which are shown to increase oxidative stress, are ideal
candidates for HNSCC therapy. However, ROS are still regarded as key meditators in numerous
cellular pathways that lead to growth and survival, warranting a proper investigation in ROS
inducing anti-cancer agents [23]. Traditionally, the research on ROS-inducing anti-neoplastic
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drugs focused on whether the treatment kills cancer cells, and little attention has gone in to
understanding how ROS inducers may effect migration and invasion [23,110]. The conundrum
of ROS therapy is that ROS inducing agents are strongly associated with increased migration and
invasion of cancer cells [112,113]. However, a study by Luanpitpong et al. (2010) showed that
in HN460 lung cancer cells certain ROS (OH•) increased cell migration while others (O2 and
H2O2) decreased cell migration. This same study indicated that catalase, which is a H2O2
scavenger, increased migration [114].
Results from our lab using HNSCC cells support the findings of Luanpitpong et al.
(2010) and suggest that the type of ROS induced may be important in modulating HNSCC cell
migration [114]. Here we show that BITC treatments significantly induced ROS and suppressed
cell migration in HNSCC cell lines and that by modulating BITC induced ROS levels with either
N-acetyl-L-cysteine (NAC) or catalase we restored HNSCC cell migration. In regards to
decreased cell viability in HNSCC cell lines, we have shown that NAC inhibited the additive
effects of BITC pretreatment followed by cisplatin.
In conclusion, BITC targets many molecular pathways in the cell that alter migration,
invasion, and cell death. Here, we demonstrate that ROS play an important role in the ability of
BITC to alter migration and invasion and induce cell death.
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MATERIALS AND METHODS

Materials
Benzyl isothiocyanate (99.5% pure) was purchased from LKT Laboratories, Inc. (St.
Paul, MN). Stock solutions of BITC (100mM) were prepared in DMSO and diluted into growth
medium such that the final concentration of DMSO did not exceed 0.01% (vol./vol.), a
concentration that did not induce toxicity in HN12 and HN30 cells. 2',7'dichlorodihydrofluorescein diacetate (H2DCFDA) was purchased from Molecular Probes (Grand
Island, NY). Stock solutions of H2DCFDA (50mM) were prepared in DMSO in the dark and
diluted into serum free growth medium. N-Acetyl-L-cysteine (NAC) and Catalase from bovine
liver were both purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions of NAC
(100mg/mL) were prepared in sterile Milli-Q water and diluted into serum free growth medium.
Catalase treatments (2,500U/mL) were prepared in serum free growth medium. CisDiammineplatinum (II) dichloride (CDDP) was purchased from Sigma-Aldrich (St. Louis, MO).
Stock concentrations of CDDP (1mg/1mL) were prepared in a 0.9% sterile saline solution.

Cell Culture and Reagents
The highly metastatic HNSCC cell line, HN12, and moderately metastatic HNSCC cell
line, HN30, were a kind gift from Dr. George Yoo (Karmanos Cancer Center, Wayne State
University, OH) [44,91]. Monolayer cultures of HN12 and HN30 were maintained in
Dulbecco’s Modified Eagles Medium (DMEM) (HyClone, Thermo-Scientific) adjusted to
contain 10% fetal bovine serum (FBS) (PAA Laboratories GmbH, Pasching, Austria) and
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supplemented with 1% (vol./vol.) penicillin-streptomycin (P/S) (Corning Cellgro, Manassas,
VA). Cells were grown in a humidified incubator at 37oC and with 5% CO2.

Intracellular ROS Generation
Cells were seeded in 6-well plates (3x105 cells/well) 24 hours prior to treatment. Levels
of intracellular ROS were determined using 5-(and-6-) chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Molecular Probes, Eugene, OR). Cells were
washed twice with 1X Dulbecco’s PBS (PBS) (GIBCO, Invitrogen) and incubated for 5 minutes
in the presence or absence of 2.5μM H2DCFDA in serum free DMEM. Following a 5 minute
incubation, cells were washed three times with 1X PBS and treated with BITC (1.25-10μM),
5mM NAC, 2,500U catalase, or a combination of BITC and NAC or BITC and catalase for 1
hour. After treatment cells were washed two times with 1X PBS and then incubated with
StemPro® Accutase® (Life Technologies, Grand Island, NY) for 5 minutes. H2O2 (10μM) was
used as positive control. Cells were collected and transferred to 1.5mL microcentrifuge tubes
and spun down at 400xg for 5 minutes. The supernatant was removed and cells were washed
two times with 500μL PBS. Cells were re-suspended in 400μL of PBS and kept one ice and
fluorescence was determined using an Accuri C6 Flow Cytometer (BD Accuri, San Jose, CA).
Assays for intracellular ROS generation were performed in technical triplicates and biological
triplicates.

Immunofluorescence
Cells were seeded and treated as described above in the Intracellular ROS Generation
methods. After treatment cells were washed two times with 1X PBS. Wells were filled with 2
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mL of PBS prior to microscopy. Images were taken using an Olympus IX51 inverted
microscope equipped with epifluorescence (Olympus, Center Valley, PA).

NF-κBp50 activity assay
NF-κBp50 activity was evaluated in HNSCC cell lines 24 hours after a 1-hour BITC
treatment using an NF-κB p50 Transcription Factor Kit (Pierce Biotechnology, Rockford, IL),
according to manufacturer’s protocol. The kit contains streptavidin-coated 96-well plates and an
NF-κB biotinylated-consensus sequence. Only the active form of NF-κB will bind to the DNA
consensus sequence. A wild type NF-B competitor and a mutant NF-B competitor were used
to ensure the signal specificity of the assay. A TNFα activated HeLa cell nuclear extract was
used as a positive control. HNSCC cell pellets were lysed after treatment with RIPA buffer (1%
NP-40, 0.1% SDS, 50mM Tris-HCl pH 7.4, 150mM NaCl, 0.5% Sodium Deoxycholate, 1mM
EDTA). Protein extracts containing 5µg of protein/well were added in triplicates to appropriate
microplate wells. Luminescence resulting from a reaction with bound NF-κB was detected using
a SpectraMax L plate reader (Molecular Devices, Sunnyvale, CA).

Co-treatment MTT Cell Viability Assay
HN12 and HN30 cells were seeded at an initial density of 5x103 cells/well in 96-well
tissue culture plates (Corning, Corning, NY) and allowed to settle overnight. Cells were treated
with BITC (2.5-10μM), 5mM NAC, 2,500U/mL catalase, and a combination of BITC and NAC
or BITC and catalase for 1-hour. All treatments were prepared in DMEM containing 0.05%
FBS, 1% P/S. After 1-hour plates were washed and media was replaced with fresh DMEM
containing 10% FBS, 1% P/S. The cell viability was determined after 24- and 48-hours using
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thiazolyl blue tetrazolium bromide (Sigma-Aldrich, St. Louis, MO). Cells were incubated with
the dye for 2 hours, and then media was removed and replaced with DMSO. Color development
in the plates, which is correlated with the metabolic activity of living cells, was read at 590nm
using the SpectraMax M2e plate reader (Molecular Devices, Sunnyvale, CA).

Pre-treatment MTT Cell Viability Assay
HN12 and HN30 cells were seeded as described above in Co-treatment MTT Cell
Viability Assay methods. Cells were treated with 1) BITC (2.5-10µM) for 1-hour, 2) a 1-hour
pretreatment of NAC followed by a 1-hour BITC (2.5-10µM) treatment, 3) NAC alone for 1hour, or 4) appropriate vehicle control. All treatments were prepared in DMEM containing
0.05% FBS, 1% P/S. After 1-hour of treatment MTT assay was performed as described above in
Co-treatment MTT Cell Viability Assay methods.

Wound-Healing Assay
Cell migration was determined using a wound-healing assay. HN12 cells were cultured
in DMEM containing 10% FBS, and 1% Pen-Strep in 6-well plates until 90% confluent, and then
media was changed to DMEM with 0.05% FBS and 1% P/S overnight to synchronize the cells.
A line was drawn horizontally on the bottom of each well with a permanent marker, and a plastic
pipette tip (p200) was used to generate 3 vertical scratches per well (90 degrees to the permanent
line). Cell debris were washed away with PBS and initial scratch sizes were determined with an
inverted light microscope (Olympus IX51, Center Valley, PA) at 100X magnification. Six
measurements were made per well, 1 below and 1 above the horizontal line for each scratch
before treatment. Cells were treated with 1) BITC (1.25 and 2.5μM), 2) 5mM NAC, 3)
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2,500U/mL catalase, 4) a combination of BITC and NAC, or 5) BITC and catalase for 1 hour at
37oC. DMSO, at the same concentration as in the BITC treated wells, was used for the vehicle
control. After 1-hour, plates were washed with PBS and media was replaced with DMEM (10%
FBS, 1% P/S). Wound healing was analyzed 24 hours after treatment. Images were taken at
100X magnification, as described above, and changes in cell migration were determined by
calculating the percent of wound healing. Percent wound healing= ((scatcht-0hr - scatcht24hr)/scatcht-0hr)*100.

Experiments were repeated 3 times.

MTT Cell Viability/Chemosensitivity Assay
HN12 and HN30 cells were seeded at an initial density of 5x103 cells/well in Corning 96well tissue culture plates (Corning, NY) and allowed to settle overnight. Cells were treated with
1) BITC (5μM); 2) NAC (5mM); 3) Cisplatin (10μM); 4) co-administration of BITC (5μM) and
NAC (5mM); 5) co-administration of cisplatin (10μM) and NAC (5mM) 6) a 1-hour
pretreatment of BITC (5M) followed by a treatment of CDDP (10M) for 24 hours; or 7) a 1hour pretreatment of BITC (5M) with NAC (5mM) followed by a treatment of CDDP (10M)
for 24 hours. DMSO was used for the vehicle control. Media was changed in all wells 24 hours
after cisplatin treatment prior to the 48-hour analysis. Cell viability was determined 24- or 48hours later as described above under MTT Cell Proliferation/Viability Assay methods. Results
were performed in technical quadruplets with three biological replicates.

Statistical Analysis
All experiments were performed at least three times as independent experiments.
Statistical analyses were done with a multiple comparison test with appropriate post-hoc test.
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GraphPad Prism (La Jolla, CA) was used for all statistical analysis. A p-value of <0.05 was
considered statistically significant.
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RESULTS

BITC Increases ROS in HNSCC Cell Lines
A dichlorofluorescein (DCF) assay indicated that BITC dramatically increased the ROS
production in the HN12 and HN30 cell lines (p≤0.05) (Figure 4.1). Immunofluorescence
supported the DCF flow cytometry results and indicated that BITC treatment increased ROS in
the HN12 cell line after 1-hour (Figure 4.2). The percentage of HN12 cells that fluoresced after
a 1-hour BITC treatment (2.5-10 μM) was similar, but the intensity of the DCF fluorescence was
concentration dependent (Figure 4.2).
We also observed that while the non-metastatic HN30 cell line showed a significant
increase in ROS production after BITC treatment, the increase in ROS was over 3 folds greater
in the highly metastatic HN12 cell line. Notably, while 2.5µM BITC induced significant
elevations in ROS in HN12 and HN30, this concentration of BITC did not induce significant
changes in cell viability after 24 or 48 hours
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Figure 4.1 BITC treatment significantly increases ROS in HN12 and HN30 cell lines.
DCF assay was used to determine ROS production in HN12 and HN30 cell lines 1-hour after
treatment with a range of concentrations of BITC (2.5-10µM). Dark grey bars represent HN12 cell
line. Light grey bars represent HN30 cell line. Error bars represent standard deviation. One-Way
ANOVA for Multiple Comparison with Dunnet’s Post-Hoc test (*p≤0.05; **p≤0.001; ***p≤0.0001).
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Figure 4.2 Intensity of DCF fluorescence increased in HN12 cells after BITC treatment, in a dose
dependent manner.
Immunofluorescence was determined after a 1-hour treatment BITC (2.5-10µM). Representative
immunofluorescence images depict DCF immunofluorescence, which correlates to ROS production.
Magnification 200X.
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NAC and Catalase Attenuate BITC Induced ROS
A dichlorofluorescein (DCF) assay showed that the ROS production induced by a 1-hour
BITC treatment was attenuated by the addition of N-acetyl-L-cysteine (NAC) in the HN30 and
HN12 cell line (p≤0.05) (Figure 4.3). ROS production was also significantly inhibited by
catalase in the HN12 and HN30 cell line (p≤0.05), but to a lesser extent than NAC (Figure 4.4).
Interestingly, the addition of catalase to BITC treatments kept HN30’s ROS production near
basal levels, but ROS production was markedly higher when catalase was added to BITC
treatments in the HN12 cell line.
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Figure 4.3 NAC inhibits BITC induced DCF fluorescence in the HN12 and HN30
cell lines.
DCF fluorescence was determined in the A) HN12 and B) HN30 cell line 24 hours
after a 1-hour treatment with BITC (2.5-10µM), a 1-hour co-administration of BITC
(2.5-10µM) and 5mM NAC, or a –hour treatment with 5mM NAC. DCF assay was
used to determine ROS production. Dark grey bars represent cells treated with BITC
only. Light grey bars represent cells co-treated with BITC and NAC. Error bars
represent standard deviation. One-Way ANOVA for Multiple Comparison with
Dunnet’s Post-Hoc test (*p≤0.05; **p≤0.001; ***p≤0.0001).
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Figure 4.4 Catalase inhibits BITC induced DCF fluorescence in the HN12 and HN30 cell
lines
DCF fluorescence in the A) HN12 and B) HN30 cell line after a 1-hour treatment with BITC
(2.5-10µM), a 1-hour co-administration of BITC (2.5-10µM) and Catalase (2,500U/mL), or a
1-hour treatment with Catalase (2,500U/mL) alone. . DCF assay was used to determine ROS
production. Dark grey bars represent cells treated with BITC alone. Light grey bars represent
cells treated with BITC and Catalase. Error bars represent standard deviation. One-Way
ANOVA for Multiple Comparison with Dunnet’s Post-Hoc test (*p≤0.05; **p≤0.001;
***p≤0.0001).
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NF-κBp50 Activity Increases after BITC Treatment
NF-κBp50 activity was significantly in the HN12 cell line after 24 hours of 10 μM BITC
treatment (p≤0.05) (Figure 4.5). NF-κBp50 activity was non-significantly increased in the
HN30 cell line after a 5 and 10 μM BITC treatment.

Figure 4.5 NFĸBp50 activity increases in the HN12 and HN30 cell line 24hrs after BITC
treatment.
NFĸBp50 luminescence in the A) HN12 and B) HN30 cell line. Cells were collected 24 hours after
a 1-hour treatment with BITC (5-10µM). Vehicle control was DMSO. NFĸBp50 luminescence
was normalized to protein concentration. Error bars represent standard deviation. Ctrl: negative
control. Veh: vehicle control. One-way ANOVA for multiple comparisons with Dunnet’s PostHoc test (*p≤0.05).
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The Addition of either NAC or Catalase Inhibits the Cytotoxic Effects of BITC
MTT assay results indicated that a 1-hour treatment of 5μM-10µM BITC, in DMEM with
0.5% FBS, 1% P/S significantly decreased the cell viability of the HN12 and HN30 cell lines
after 24 and 48 hours (p≤0.05) (Figure 4.6 A and B). However, a 1-hour treatment of 1.252.5μM BITC in DMEM with 0.5% FBS, 1% P/S did not significantly affect the cell viability of
these HNSCC cell lines after 24 hours and 48 hours (Figure 4.6 A and B).
Co-treatment with 5μM BITC and NAC or catalase prevented BITC from significantly
reducing HN12 and HN30 cell viability after 24 and 48 hours (p≤0.05) (Figure 4.6 and 4.7).
Importantly, our previous work demonstrated that treatment of the normal keratinocyte cell line
(HAK) with 2.5-10μM BITC did not decrease viability [44,115]. This indicates that BITC is
selectively cytotoxic against HNSCC cancer cells, and that NAC and catalase can prevent the
toxicity of BITC in HNSCC cells.

NAC Pre-treatment Followed by a BITC Treatment Decreased Cell Viability More Than
Significantly When Compared BITC Treatment Alone
MTT assay results indicate that a 1-hour pre-treatment with NAC followed by a 2.5 or
5µM BITC treatment significantly increased the cytotoxic effects of BITC in HN12 and HN30
cells (p≤0.05) (Figure 4.8 A and B). Cell viability was determined at 24 hours post-treatment.
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Figure 4.6 NAC co-administered with BITC prevents the effect of BITC treatments on
HN12 and HN30 cell viability.
MTT assay was used to determine changes in cell viability of A) HN12 or B) HN30 cell
lines 24 hours after treatment. Cells were treated with BITC (2.5-10µM), NAC+BITC
(2.5-10µM), NAC, or appropriate vehicle control for 1-hour. Percent viability was
determined comparing absorbance of treatment groups to their respective vehicle control.
Ctrl: negative control. Veh: vehicle control. Error bars represent standard deviation. Oneway ANOVA for multiple comparisons with Dunnet’s Post-Hoc test. a= significantly
different from Veh Ctrl (p≤0.0001); b=significantly different from 2.5μM BITC+NAC
(p≤0.0001); c=significantly different from 5μM BITC+NAC (p≤0.0001); d=significantly
different from Veh Ctrl (p≤0.05).
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Figure 4.7 Catalase co-administered with BITC inhibits BITC treatment from
reducing HN12 cell viability.
In the HN30 cell line, co-administered BITC and Catalase does not significantly alter cell
viability, compared to BITC treatments alone. Cells were treated with BITC (2.5-10µM)
for 1-hour, a Catalase (CAT) and BITC (2.5-10µM) co-treatment for 1-hour, Catalase
alone for 1-hour, or appropriate vehicle control (VEH). MTT assay was used to determine
changes in A) HN12 and B) HN30 cell viability 24 hours after treatment. Percent viability
was determined comparing absorbance of treatment groups to their respective vehicle
control. Error bars represent standard deviation. One-way ANOVA for multiple
comparisons with Dunnet’s Post-Hoc test. a=significantly different from Veh Ctrl
(p≤.0001); b=significantly different from 5μM BITC+ Catalase (p≤0.05); c=significantly
different from Veh Ctrl (p≤0.05)
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Figure 4.8 NAC pre-treatment followed by BITC treatment decreases HN12 and HN30
cell viability more significantly than BITC treatment alone.
Cells were treated with BITC (2.5-10µM) for 1-hour, a 1-hour pretreatment of NAC followed
by a 1-hour treatment with BITC (2.5-10µM), NAC alone for 1-hour, or appropriate vehicle
control. MTT assay was used to determine changes in A) HN12 and B) HN30 cell viability 24
hours after treatment. Percent viability was determined comparing absorbance of treatment
groups to their respective vehicle control. Ctrl: negative control. Veh: vehicle control. Error
bars represent standard deviation. One-way ANOVA for multiple comparisons with Dunnet’s
Post-Hoc test. a=significantly different from Veh (p≤0.001); b=significantly different from
2.5μM BITC (p≤0.0001); c=significantly different from Veh (p≤0.0001); d=significantly
different from 5μM BITC (p≤0.0001).
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NAC and Catalase Prevent BITC from Inhibiting Migration of HNSCC Cells
A wound-healing assay indicated that BITC inhibited the migration of the highly
metastatic HN12 cells in a dose dependent manner, after 24 hours (p≤0.05). However, NAC
(Figure 4.9A and B) and catalase (Figure 4.10 A and B) inhibited the ability of BITC to
prevent wound healing in the HN12 cell line. Under the conditions used for this assay catalase
treatment alone appeared to increase the wound healing, although this was not statistically
significant.
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Figure 4.9 NAC co-administered with BITC prevents the effect of BITC
treatments on wound healing in the HN12 cell line.
(A) Inverted light microscope images of HN12 cells 24 hours after cells were
treated with BITC (2.5-10µM) for 1-hour, a NAC and BITC (2.5-10µM) cotreatment for 1-hour, NAC alone for 1-hour, or appropriate vehicle control. Dashed
lines represent scratch size before treatment. Magnification 100X. (B) Bar
diagram represents the percent wound healing of the HN12 cell line 24 hours after
treatment. Percent wound healing was calculated using wound size measurements.
Error bars represent standard deviation. One-way ANOVA for multiple
comparisons with Dunnet’s Post-Hoc test. a= significantly different from Veh
(p≤0.05); b= significantly different from 1.25μM BITC+NAC (p≤0.05); c=
significantly different from Veh (p≤0.0001); b= significantly different from 2.5μM
BITC+NAC (p≤0.0001). Ctrl: negative control. Veh: vehicle control.
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Figure 4.10 Catalase co-administered with BITC prevents the effect of BITC
treatments on wound healing in the HN12 cell line.
(A) Inverted light microscope images of HN12 cells 24 hours after cells were treated
with BITC (2.5-10µM) for 1-hour, a Catalase and BITC (2.5-10µM) co-treatment for
1-hour, Catalase alone for 1-hour, or appropriate vehicle control. Dashed lines
represent scratch size before treatment. Magnification 100X. (B) Bar diagram
represents the percent wound healing of the HN12 cell line 24 hours after treatment.
Percent wound healing was calculated using wound size measurements. Error bars
represent standard deviation. One-way ANOVA for multiple comparisons with
Dunnet’s Post-Hoc test. a=significantly different from Veh (p≤0.001);
b=significantly different from 1.25μM BITC+Catalse (p≤0.0001); c= significantly
different from Veh (p≤0.0001); d=significantly different from 2.5μM BITC+Catalase
(p≤0.0001). Ctrl: negative control. Veh: vehicle control.
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NAC Prevents BITC Induced Chemo-enhancement
One of the major obstacles in the therapeutic use of platinum analogues is intrinsic or
acquired resistance [100-103]. Previous work from our lab indicated that BITC treatment
enhanced the effects of cisplatin (CDDP) in CDDP resistant HNSCC cell lines [115]. Our recent
results suggest that when NAC is added to 1-hour pretreatment of BITC the effects typically
induced by a pretreatment of BITC followed by CDDP are abrogated at the 24 and 48-hour time
points in the HN12 and HN30 cell lines (p≤0.05) (Table 4.1).
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Table 4.1 Percent viability of HN12 and HN30 cell lines 24 and 48 hours after treatment*.

Treatment Group

HN12 Cell Line
24hr

48hr

HN30 Cell Line
24hr

48hr

NAC

92.49 ± 8.0 c;d;e

94.04 ± 4.1 c;d;e

104.96 ± 8.3 c;d;e

82.54 ± 12.3 c;d;e

5μM BITC

47.33 ± 5.2 a;b;d

30.24 ± 1.8 a;b;d;e

79.28 ± 7.6a;b;d

54.44 ± 6.23a;b;d

5μM BITC +NAC

70.72 ± 5.9 a;b;c;d;e

87.85 ± 1.71 a;c;e

76.66 ± 4.5 a;b;c;d;e

89.57 ± 10.8 b;c;d;e

5μM BITC; 10μM CDDP

30.68 ± 3.6 a;b;c;d

11.64 ± 1.49 a;b;e

41.54 ± 10.32 a;b;c;d

18.95 ± 7.6 a;b;c;d

5μM BITC +NAC; 10μM CDDP

101.32 ± 9.2 b;c

64.71 ± 8.2 a;c;e

83.05 ± 13.8 c;e

48.08 ± 17.7 a;b;e

10μM CDDP

70.37 ± 13.2b;c

60.58 ± 10.1 a;c;e

62.53 ± 5.5 a;b;c;d

50.33 ± 6.06 a;b;e

NAC; 10μM CDDP

86.34 ± 12.3 b;e

64.35 ± 13.2 a;b;e

81.47 ± 12.3 b;e

52.00 ± 9.78 a;b;e

*Percent viability ± standard deviation was calculated comparing MTT absorbance of treatment groups to their
respective vehicle control. Cells were treated with BITC alone for 1-hour, NAC alone for 1-hour, Cisplatin (CDDP)
alone for 24-hours, co-administration of BITC and NAC for 1-hour, NAC for 1- hour followed by CDDP for 24hours, a 1-hour pretreatment of BITC followed by a treatment of CDDP for 24 hours; or a 1-hour pretreatment of
BITC and NAC followed by a treatment of CDDP (10M) for 24 hours. a=significant difference from respective
Vehicle Control; b=significant difference from Vehicle Control + NAC; c=significant difference from 5μM BITC;
d=significant difference from 10μM CDDP; e=significant difference from a 5μM BITC pretreatment followed by a
10μM CDDP
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DISCUSSION

Previous studies from our lab indicated that BITC has a dual function of targeting both
cell viability and cell migration [44,116]. BITC, like other ITCs, targets a variety of molecular
pathways making it difficult to pinpoint how BITC elicits its therapeutic response in HNSCC
cells [2,116]. However, the results of the present study demonstrate that BITC induced ROS
regulates both HNSCC cell viability and migration. By attenuating BITC induced ROS with
NAC and catalase we were able to inhibit BITC’s ability to prevent cell migration and add to the
effects of cisplatin.
NAC and catalase are both antioxidants that scavenge free radicals. NAC is a GSH
precursor and thereby increases cellular GSH [23,117,118]. Cellular GSH plays a central role in
maintaining redox homeostasis, and reduced GSH act as a direct scavenger of ROS by reacting
with singlet oxygen, hydroxyl radicals, and superoxide radicals [23]. We used NAC to
investigate a mechanism of action of BITC in HNSCC cells. NAC in combination with ITCs has
been used to investigate ITC’s mechanism of action in other cell lines, and recently Gong et al.
(2009) used NAC in combination with ITCs to support that ROS alters STAT3 activation in
prostate cancer cells [14].
In our study BITC treatments significantly increased ROS production in HNSCC cell
lines. An increase in NF-κBp50 activity in HNSCC cells supports that the increased ROS has
downstream effects. However, an increase in NF-κBp50 is novel and an inhibition of NF-κBp50
is observed in other cancer cell lines.
BITC initiated ROS production was significantly decreased when NAC and BITC were
co-administered. Additionally, NAC prevented BITC induced cytotoxicity. However, our data
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supports that the timing of NAC administration is critical to its ability to attenuate the effects of
BITC. In our experiments, when NAC was administered an hour before BITC treatment its
effects were markedly different. NAC pretreatment enhanced BITC induced cytotoxicity. High
levels of cellular GSH support isothiocyanate uptake, and this could explain why pretreatment of
NAC increases BITC induced cytotoxicity [11,105,119,120]. NAC also alters redox status in
cells and we speculate that the pretreatment with NAC could increase the effects BITC induced
ROS, whereas when NAC and BITC were co-administered, NAC inhibited BITC induced ROS
[11,35,110]. This highlights the challenge of understanding the link between ROS, BITC, and
cellular function.
More investigation on the relationship between BITC and NAC will be needed, but the
relationship between BITC and NAC co-administration should not be overlooked. Regardless of
why NAC inhibited ROS production, it is still evident that NAC prevented the therapeutic effects
of BITC when co-administered. This knowledge is still critical for future clinical trials. Our
results stress the importance of a monitoring a patient’s antioxidant consumption, because our
data supports that administering BITC with NAC would have not been beneficial for a patient.
Our data is also interesting because other research groups have found that NAC coadministration enhances the effects of certain anti-cancer agents, such as retinoic acid [121,122].
Catalase is a scavenger of H2O2 and we used this reagent to further support the NAC
studies. Catalase significantly prevented BITC induced ROS production in the HNSCC cell
lines. The prevention of ROS production was not to the same extent as NAC, probably because
catalase is more specific in its ROS scavenging abilities. Catalase did, however, highlight the
potential of H2O2 induction in HNSCC cell lines. Furthermore, catalase alone appeared to
increase HNSCC cell migration, which is interesting because several reports suggest that
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increasing ROS production is usually associated with increased cellular migration [112,113].
Our results are supported by Luanpitpong et al. (2010) and because their study also showed that
catalase stimulated cell migration while H2O2 inhibited cellular migration [114]. Inokuma et al.
(2012) also suggest that increased ROS is pertinent to preventing lymph node metastasis in
colorectal cancer [123]. Furthermore, Das et al. (2012) report that ROS generation inhibits EMT
and promotes growth arrest in prostate cancer cells [124]. Taken together, our results combined
with others indicate that investigating ROS as a whole may lead to confounding results. Our
results support the notion that specific types of ROS combined with the molecular pathways that
are altered in certain cancer cells can have nontraditional results.
In addition to preventing cellular migration we also showed that NAC and catalase
prevented BITC induced cytotoxicity in the HNSCC cells. NAC also prevented BITC’s ability
to enhance the effects of the cisplatin in reducing cell viability. The platinum compound,
cisplatin, is regarded as one of the standard-of-care treatments for HNSCC, and is typically used
in combination radiation or other agents [78,125,126]. Initial or acquired resistance to platinum
compounds greatly hinder outcome for HNSCC patients and high levels of drug detoxifying
agents are linked to cisplatin resistance [126]. Two such drug-detoxifying agents linked to
cisplatin resistance are high levels of GSH and catalase.
However, one way cisplatin induces cell death is by increasing ROS. This evidence
supports the mechanism that lower cellular ROS lead to cisplatin resistance. Therefore, using
NAC to increase cellular GSH and catalase to scavenge H2O2 we could be preventing the
mechanism through which BITC enhances cisplatin toxicity. Our results showing that by
pretreating the HNSCC cells with BITC the ROS were increased and could explain why we
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observed increased cell death in platinum-resistant HNSCC cells pretreated with BITC followed
by cisplatin.
In conclusion, the present study sets the framework for future investigation into the
mechanism through which BITC inhibits migration and invasion, as well as induces
chemoensensitivity. Our study suggests that ROS generation is one important mechanism by
which BITC elicits its response. Future studies, will work to continue to unravel the role of ROS
in HNSCC by including experiments to evaluate the role of antioxidants, like vitamin E that
affects the lipid bilayer, to further improve our understanding of mechanisms involved in
chemoresistance or chemosensitivity of HNSCC cells. Additionally, future in vivo studies will
shed the greatest light on the potential and feasibility of BITC as an adjuvant to anti-cancer
agent.

AKNOWLEDGEMENTS
We are grateful to Dr. Johannes Fahrmann for critical review of the manuscript.

FUNDING
We gratefully acknowledge the Marshall University Biochemistry and Microbiology & Surgery
Departments for their support. The present studies were supported by the NASA WV Space
Grant Consortium, award #NNX10AK62H. The funder had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.

93

Chapter 5 : Conclusion and Future Direction

In Chapter 1, we reviewed current literature on ITCs and highlighted the potential of ITC
treatments as adjuvant cancer therapy. We chose to specifically focus on ITC as a therapy for
HNSCC, because, as discussed in Chapter 2 the quality of life in response to current therapy for
advanced HNSCC is poor. We focused specifically on BITC as an additive to current
chemotherapy because this ITC elicited the strongest anti-tumor response in HNSCC cells. In
Chapter 3, we demonstrated that after 24 and 48 hours BITC treatment significantly reduced the
viability of multiple HNSCC cell lines tested (HN12, HN8, and HN30), but not a normal
keratinocyte line (HAK). Treatment with BITC also decreased migration and invasion of the
HN12 cell line and inhibited expression and altered localization of the EMT marker, vimentin.
We also reported that a pretreatment of BITC followed by a treatment with cisplatin decreased
HN12, HN30, and HN8 cell viability and proliferation greater than when compared to either
treatment alone. Pretreatment with BITC followed by a cisplatin treatment also increased
apoptosis more than either treatment alone. Additionally, BITC treatment decreased expression
of the anti-apoptotic protein, bcl-2.
Current therapies can be further improved if we understand the mechanism through
which our treatments elicit and anti-tumor response. In Chapter 4, we discussed how treatments
with BITC significantly increased ROS production in HNSCC cell lines. NAC and catalase
attenuated this increase in ROS production. ROS is a complex topic and presents an interesting
paradox in cancer. Literature supports the hypothesis that ROS can be carcinogenic or suppress
cancer progression. Our particular study indicates that in this model ROS production elicits and
anti-cancer response, because at low concentrations BITC induced ROS production and limited
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HNSCC cell migration however, when using higher concentrations of BITC, ROS decreased cell
viability.
Literature reveals that ITCs, including BITC, target many molecular pathways and our
present body of work suggest that increased in ROS is one mechanism through which BITC
treatments targets HNSCC cells. As previously mentioned, ROS is a complex topic in relation to
cancer therapy. Our investigation only begins to unravel the role of ROS in HNSCC. More
work will be needed to fully understand the role of BITC induced ROS. Such studies would
incorporate other anti-oxidant products into BITC treatments. Vitamin E is one example of an
anti-oxidant that would increase our understanding of mechanism involved in BITC induced
ROS in HNSCC cells, because it is a lipid soluble anti-oxidant that prevents lipid membrane
peroxidation. Signaling from the lipid membrane can alter many cellular functions. Additional
studies investigating the effect of BITC on GSH could increase our knowledge of BITC’s
mechanism of action. Preliminary data also suggest that studying the effect of BITC on multidrug transporters could highlight additional targets of BITC.
In addition the experiments suggested above, we propose several other future studies to
further increase our understanding of BITC’s potential as an adjuvant therapy. Our preset
investigation only studied one type of HNSCC therapy in conjunction with BITC. The potential
of BITC to add to or synergize other HNSCC therapies is high. Developing an HNSCC animal
model to study BITC as an adjuvant therapy will increase our understanding of BITC in an in
vivo setting. Future work should investigate BITC in combination with other chemotherapies as
well as radiation therapy.
A shortcoming of our present studies is the lack of in vivo data, however, studies by other
groups suggest that in vitro results correlate with in vivo observations.
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In conclusion, our present body of work supports that BITC is a promising adjuvant
chemotherapy for HNSCC. The studies on BITC presented in this thesis suggest that this
therapeutic option is worth exploring on a larger scale. Progression of our current study from
bench to bedside will ultimately determine if inclusion of BITC as adjuvant therapy option for
HNSCC will improve patient outcome and quality of life.
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